JP2019048815A - インスリン分泌促進性ペプチドの懸濁製剤及び使用 - Google Patents
インスリン分泌促進性ペプチドの懸濁製剤及び使用 Download PDFInfo
- Publication number
- JP2019048815A JP2019048815A JP2018193825A JP2018193825A JP2019048815A JP 2019048815 A JP2019048815 A JP 2019048815A JP 2018193825 A JP2018193825 A JP 2018193825A JP 2018193825 A JP2018193825 A JP 2018193825A JP 2019048815 A JP2019048815 A JP 2019048815A
- Authority
- JP
- Japan
- Prior art keywords
- delivery device
- formulation
- suspension
- osmotic
- osmotic delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C07K7/067—Hemoregulatory peptides based on sequence Glp-Glu-Asp-Cys-Lys
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/494—Fluidic or fluid actuated device making
Abstract
Description
本出願は、2007年4月23日に出願された米国仮出願第60/926,005号、及び2008年5月28日に出願された米国仮出願第61/072,202号の利益を主張し、これらの出願は本明細書中で、それらの全てが参照により援用される。
本発明は、医薬研究開発に応用される、有機化学、製剤化学、及びペプチド化学に関する。本発明の側面は、哺乳類における使用のための、及び疾患又は病態の処置のための、インスリン分泌促進性ペプチドの懸濁製剤を提供する。
グルカゴン様ペプチド-1(GLP-1)は、重要なホルモンの1つであり、そしてヒトプログルカゴン分子のフラグメントである。GLP-1は、ペプチダーゼ(ジペプチジルペプチダーゼIV又はDPP-IV)により急速に代謝される。GLP-1のフラグメントであるグルカゴン様ペプチド-1(7-36)アミド(グルカゴン様インスリン分泌促進性ペプチド、又はGLIP)は、生理的濃度でインスリンの放出を促進する胃腸ペプチドである(Gutniak M., et al., N Engl J Med. 1992 May 14;326(20):1316-22)。GLP-1及びGLP-1(7-36)アミドは、インクレチンである。インクレチンは、食後にベータ細胞から放出されるインスリンの量の増大を引き起こす胃腸ホルモンである。
本発明は、粒子製剤及び懸濁ビヒクルを含む懸濁製剤組成物、並びにそのような製剤を含む装置、そのような製剤及び装置を作製する方法、並びにそれらを使用する方法に関する。
本明細書中に引用される全ての特許、刊行物、及び特許出願は、各々個別の特許、刊行物、又は特許出願が、本明細書の全てにおいてあらゆる目的で参照により援用されることを特異的にかつ個別に示したが如く、本明細書中で参照により援用される。
本明細書中で使用される専門用語は唯特定の態様を記載することのみを目的とし、そして限定を意図するものではないことが理解されるべきである。本明細書及び添付された特許請求の範囲において使用されるとき、単数形の「ある(a)」、「ある(an)」及び「その(the)」は、文脈中に明確な別段の指示が無い限り、複数の対象を含む。故に、例えば、「ある溶媒」の参照は、2つ以上のそのような溶媒の組合せを含み、「あるペプチド」の参照は、1つ以上のペプチド、複数のペプチドの混合物等を含む。
[式中、
F/A=せん断応力(単位面積当たりの力)
μ=比例定数(粘性)
V/L=層の厚さあたりの速度(せん断速度)]
本発明を詳細に記載する前に、本発明は、特定の種類の薬物送達、特定の種類の薬物送達装置、特定のペプチドの供給源、特定の溶媒、特定のポリマー等に限定されないことを理解されたい。なぜなら、そのような特定の物の使用は、本発明の教示を考慮して選択され得るからである。また、本明細書中で使用される技術は、本発明の特定の態様を記載することのみを目的とし、限定を意図しないことも理解されたい。
2.1.1 粒子製剤
一の態様において、本発明は、例えばGLP-1又はエクセナチド等のインスリン分泌促進ペプチドの懸濁製剤を含む医薬組成物を提供する。上記懸濁組成物は、少なくとも1つのポリマー及び少なくとも1つの溶媒を含む、非水性単相ビヒクルを含む。前記ビヒクルは、好ましくは、粘性流体特性を呈する。前記ペプチド成分は、前記ビヒクル中に分散した粒子製剤中に前記インスリン分泌促進ペプチドを含む。典型的には、前記粒子製剤は、糖質、抗酸化剤、アミノ酸、緩衝剤、及び無機化合物からなる群から選択される1つ以上の安定化剤成分を含む安定化成分を含む。
本発明の一の側面において、前記懸濁ビヒクルは、インスリン分泌促進性ペプチド粒子製剤がその中で分散する安定な環境を提供する。前記粒子製剤は、前記懸濁ビヒクル中で化学的及び物理的に安定(上記と同じ)である。前記懸濁ビヒクルは、インスリン分泌促進性ペプチドを含む粒子が均一に懸濁するのに十分な粘性を有する溶液を形成する1つ以上のポリマー及び1つ以上のビヒクルを典型的に含む。
本明細書中に記載される懸濁製剤は、数週、数ヶ月、又は約1年に渡る長期間、化合物の持続的な送達を提供するために、移植可能な薬物送達装置に使用され得る。そのような移植可能な薬物送達装置は、典型的には、所望の期間にかけて所望の流量で化合物の送達を可能とする。前記懸濁製剤は、通常の技術により、その移植可能な薬物送達装置に充填される。
本明細書中に記載される懸濁製剤は、糖尿病の対象におけるインスリン療法の有望な代替手段を提供する。糖尿病タイプ2又は2型糖尿病(インスリン非依存性糖尿病(NIDDM))は、インスリン耐性、相対的なインスリン欠乏、及び高血糖により原始的に特徴付けられる代謝疾患である。インスリン分泌促進性ペプチドを含む本発明に係る懸濁製剤は、インスリン分泌の刺激、グルカゴン分泌の抑制、胃内容排出の遅延、及び場合によっては筋及び脂肪等の末梢組織におけるインスリン感受性の亢進において有用である。
以下の実施例は、当業者に対し、本発明に係る装置、方法、及び製剤を製造及び使用する方法の完全な開示及び記載を提供するように提示されるものであり、発明者が発明とみなすものの範囲を限定することを意図しない。使用される数値(例えば量、温度等)に関しては正確を期するよう努めているが、ある程度の実験的錯誤及び偏差が含まれ得る。示唆されていない限り、部とは重量部であり、分子量は平均分子量であり、温度はセルシウス度であり、そして圧力は大気圧又はその付近である。
エクセナチド粒子製剤
この実施例は、エクセナチド粒子製剤の作製を記載する。
エクセナチド(0.25g)は、pH6.04の50mMクエン酸ナトリウム緩衝液中に溶解された。前記溶液は、クエン酸ナトリウム、スクロース、及びメチオニンを含む製剤溶液で透析された。そして前記製剤化溶液は、0.7mmノズルを備え、出口温度が75℃であり、気化圧力が100Psiであり、固体含有率が2%であり、そして流速が2.8mL/minであるBuchi290を使用して噴霧乾燥された。前記乾燥粉末は、21.5%のエクセナチドと4.7%の残留水分を含み、密度は0.228g/mlであった。
2つの追加的なエクセナチドの製剤が、本質的に先述の方法により調製された。以下の表3において、前記製剤1、2、及び3の構成成分の重量パーセント(wt%)がまとめられている。
GLP-1乾燥粉末
この実施例は、GLP-1(7-36)アミド粒子製剤の作製を記載する。
GLP-1(7-36)アミド(1.5g)は、pH4の5mMクエン酸ナトリウム緩衝液中に溶解された。前記溶液は、クエン酸ナトリウム緩衝剤及びメチオニンを含む製剤溶液で透析された。そして前記製剤化溶液は、0.7mmノズルを備え、出口温度が70℃であり、気化圧力が100Psiであり、固体含有率が1.5%であり、そして流速が5mL/minであるBuchi290を使用して噴霧乾燥された。前記乾燥粉末は、90%のGLP-1(7-36)アミドを含んでいた。
エクセナチド懸濁製剤
この実施例は、懸濁ビヒクル及びエクセナチド粒子製剤を含む懸濁製剤の作製を記載する。
エクセナチド粒子製剤は噴霧乾燥により製造され、そして20wt%のエクセナチド、32wt%のスクロース、16wt%のメチオニン、及び32wt%のクエン酸緩衝剤を含んでいた。
懸濁ビヒクルは、乾燥大気中で、及び減圧下で、ポリビニルピロリドンK-17(典型的には、平均分子量が約7,900〜10,800の範囲にある)ポリマーを、約65℃まで加熱した安息香酸ベンジル溶媒中に、約50/50の重量比率で溶解することにより形成された。前記ビヒクルの粘性は、33℃で測定されたとき、約12,000〜18,000ポアズであった。実施例1に記載の粒子製剤1〜3は、表4に示される濃度(重量パーセント)で、前記ビヒクル全体に分散した。
GLP-1(7-36)アミド製剤
この実施例は、懸濁ビヒクル及びGLP-1(7-36)アミド粒子製剤を含む懸濁製剤の作製を記載する。GLP-1(7-36)アミド粒子製剤は、噴霧乾燥により製造され、そして90wt%のGLP-1、5wt%のメチオニン、及び5wt%のクエン酸緩衝液を含んでいた。
DUROS(登録商標)装置を使用したエクセナチドの持続的送達による処置動物におけるグルコースレベルの低下及び体重減少
この実施例におけるデータは、DUROS(登録商標)装置からのエクセナチド製剤の持続的かつ構成的な送達の、2型糖尿病のZucker Diabetic Fatty(ZDF)ラットモデルにおけるグルコースレベル及び体重に対する影響を示した。
Claims (22)
- 浸透圧送達装置であって:
浸透圧エンジン区画と、薬物容器とを備える容器;
薬物容器中に配置された懸濁製剤;
浸透圧エンジン区画中に配置された浸透圧エンジン;
浸透圧エンジン区画中に配置された浸透圧エンジンから薬物容器中に配置された懸濁製剤を隔離するピストン;
容器の浸透圧エンジンに隣接する第一の末端に配置される速度制御式透水性膜;及び
容器の懸濁製剤に隣接する第二の末端に配置される拡散調節膜;
を備え、前記懸濁製剤が、
インスリン分泌促進性ペプチド、二糖、メチオニン、及び緩衝剤を含有する粒子製剤、ここで、(i)インスリン分泌促進性ペプチドが、エクセナチドであり、(ii)粒子製剤の粒子中のインスリン分泌促進性ペプチドとメチオニン+二糖との重量パーセント比が、1/10〜10/1であり、かつ(iii)粒子製剤の粒子の直径が50μm未満である;及び
20wt%〜60wt%の安息香酸ベンジル及び80wt%〜40wt%のポリビニルピロリドンを含有する非水性単相懸濁ビヒクル、ここで、(i)当該単相懸濁ビヒクルは、粘性流体としての特性を呈し、(ii)当該単相懸濁ビヒクルの粘性は、33℃で12000〜18000ポアズであり、かつ(iii)前記粒子製剤が当該単相懸濁ビヒクル中に分散されている;
を含み、更に、5μg/日〜600μg/日のインスリン分泌促進性ペプチドのゼロ次放出を提供する、浸透圧送達装置。 - 浸透圧送達装置であって:
浸透圧エンジン区画と、薬物容器とを備える容器;
薬物容器中に配置された懸濁製剤;
浸透圧エンジン区画中に配置された浸透圧エンジン;
浸透圧エンジン区画中に配置された浸透圧エンジンから薬物容器中に配置された懸濁製剤を隔離するピストン;
容器の浸透圧エンジンに隣接する第一の末端に配置される速度制御式透水性膜;及び
容器の懸濁製剤に隣接する第二の末端に配置される拡散調節膜;
を備え、前記拡散調節膜が、直径100μm〜500μmの送達オリフィスを有し;前記懸濁製剤が、
インスリン分泌促進性ペプチド、二糖、メチオニン、及び緩衝剤を含有する粒子製剤、ここで(i)インスリン分泌促進性ペプチドが、エクセナチドであり、かつ(ii)粒子製剤の粒子中のインスリン分泌促進性ペプチドとメチオニン+二糖との重量パーセント比が、1/10〜10/1である;及び
20wt%〜60wt%の安息香酸ベンジル及び80wt%〜40wt%のポリビニルピロリドンを含有する非水性単相懸濁ビヒクル、ここで、(i)当該単相懸濁ビヒクルは、粘性流体としての特性を呈し、(ii)当該単相懸濁ビヒクルの粘性は、33℃で12000〜18000ポアズであり、かつ(iii)前記粒子製剤が当該単相懸濁ビヒクル中に分散されている;
を含み、更に、5μg/日〜600μg/日のインスリン分泌促進性ペプチドのゼロ次放出を提供する、浸透圧送達装置。 - 前記インスリン分泌促進性ペプチドがエクセナチドである、請求項1又は2のいずれか1項に記載の浸透圧送達装置。
- 前記エクセナチドが配列番号2のアミノ酸配列を有する、請求項3に記載の浸透圧送達装置。
- 前記インスリン分泌促進性ペプチドがエクセナチドであり、5μg/日〜160μg/日の速度で均一に送達される、請求項3又は4のいずれか1項に記載の浸透圧送達装置。
- 前記粒子製剤の粒子中のインスリン分泌促進性ペプチドと、メチオニン+二糖との間の重量パーセントの比率が、1/5〜5/1である、請求項1〜5のいずれか1項に記載の浸透圧送達装置。
- 前記緩衝剤が、クエン酸塩、ヒスチジン、コハク酸塩、及びそれらの混合物からなる群から選択される、請求項1〜6のいずれか1項に記載の浸透圧送達装置。
- 前記緩衝剤がクエン酸塩である、請求項7に記載の浸透圧送達装置。
- 前記二糖が、ラクトース、スクロース、トレハロース、セロビオース、及びそれらの混合物からなる群から選択される、請求項1〜8のいずれか1項に記載の浸透圧送達装置。
- 前記二糖がスクロースである、請求項9に記載の浸透圧送達装置。
- 前記粒子製剤が、粒子の噴霧乾燥調製物である、請求項1〜10のいずれか1項に記載の浸透圧送達装置。
- 前記粒子製剤が、粒子の凍結乾燥調製物である、請求項1〜11のいずれか1項に記載の浸透圧送達装置。
- 前記ビヒクルが、50%の溶媒と50%のポリマーである、請求項1〜12のいずれか1項に記載の浸透圧送達装置。
- 前記懸濁製剤の全体含水率が10wt%以下である、請求項1〜13のいずれか1項に記載の浸透圧送達装置。
- II型糖尿病の治療を要する対象におけるII型糖尿病の治療のために用いられる請求項1〜14のいずれか1項に記載の浸透圧送達装置であって、1ヶ月〜1年の期間、当該浸透圧送達装置から均一な速度で当該対象に懸濁製剤を送達することができる、浸透圧送達装置。
- 前記装置を除去することにより、前記懸濁製剤の送達を即座に停止することができる、請求項15に記載の浸透圧送達装置。
- 肥満の治療を要する対象における肥満の治療のために用いられる請求項1〜14のいずれか1項に記載の浸透圧送達装置であって、1ヶ月〜1年の期間、当該浸透圧送達装置から均一な速度で当該対象に懸濁製剤を送達することができる、浸透圧送達装置。
- 前記装置を除去することにより、前記懸濁製剤の送達を即座に停止することができる、請求項17に記載の浸透圧送達装置。
- 前記粒子製剤が直径10μm未満の粒子を含有する、請求項1〜18のいずれか1項に記載の浸透圧送達装置。
- 前記浸透圧送達装置の容器に懸濁製剤を充填することを含む、請求項1〜19のいずれか1項に記載の浸透圧送達装置を製造する方法。
- 更に、粒子製剤を噴霧乾燥し、当該噴霧乾燥粒子製剤を単相懸濁ビヒクル中に分散して、これを懸濁製剤として、浸透圧送達装置の容器に充填することを含む、請求項20に記載の浸透圧送達装置を製造する方法。
- 更に、粒子製剤を凍結乾燥し、当該凍結乾燥粒子製剤を単相懸濁ビヒクル中に分散して、これを懸濁製剤として、浸透圧送達装置の容器に充填することを含む、請求項20に記載の浸透圧送達装置を製造する方法。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021125462A JP2021178848A (ja) | 2007-04-23 | 2021-07-30 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
JP2023171430A JP2023166021A (ja) | 2007-04-23 | 2023-10-02 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92600507P | 2007-04-23 | 2007-04-23 | |
US60/926,005 | 2007-04-23 | ||
US7220208P | 2008-03-28 | 2008-03-28 | |
US61/072,202 | 2008-03-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016187105A Division JP6802019B2 (ja) | 2007-04-23 | 2016-09-26 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021125462A Division JP2021178848A (ja) | 2007-04-23 | 2021-07-30 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019048815A true JP2019048815A (ja) | 2019-03-28 |
Family
ID=39651340
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010506245A Active JP5351884B2 (ja) | 2007-04-23 | 2008-04-22 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
JP2013173812A Active JP6016733B2 (ja) | 2007-04-23 | 2013-08-23 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
JP2016187105A Active JP6802019B2 (ja) | 2007-04-23 | 2016-09-26 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
JP2018193825A Pending JP2019048815A (ja) | 2007-04-23 | 2018-10-12 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
JP2020000461A Pending JP2020094055A (ja) | 2007-04-23 | 2020-01-06 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
JP2021125462A Pending JP2021178848A (ja) | 2007-04-23 | 2021-07-30 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
JP2023171430A Pending JP2023166021A (ja) | 2007-04-23 | 2023-10-02 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010506245A Active JP5351884B2 (ja) | 2007-04-23 | 2008-04-22 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
JP2013173812A Active JP6016733B2 (ja) | 2007-04-23 | 2013-08-23 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
JP2016187105A Active JP6802019B2 (ja) | 2007-04-23 | 2016-09-26 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020000461A Pending JP2020094055A (ja) | 2007-04-23 | 2020-01-06 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
JP2021125462A Pending JP2021178848A (ja) | 2007-04-23 | 2021-07-30 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
JP2023171430A Pending JP2023166021A (ja) | 2007-04-23 | 2023-10-02 | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
Country Status (19)
Country | Link |
---|---|
US (5) | US8299025B2 (ja) |
EP (1) | EP2157967B1 (ja) |
JP (7) | JP5351884B2 (ja) |
KR (1) | KR101208381B1 (ja) |
CN (3) | CN105688191A (ja) |
AU (1) | AU2008244523B2 (ja) |
CA (1) | CA2683610C (ja) |
CY (1) | CY1114178T1 (ja) |
DK (1) | DK2157967T3 (ja) |
ES (1) | ES2402172T3 (ja) |
HK (2) | HK1200336A1 (ja) |
HR (1) | HRP20130259T1 (ja) |
IL (5) | IL201175A (ja) |
MX (1) | MX2009011123A (ja) |
NZ (1) | NZ580447A (ja) |
PL (1) | PL2157967T3 (ja) |
PT (1) | PT2157967E (ja) |
RU (1) | RU2440097C2 (ja) |
WO (1) | WO2008133908A2 (ja) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7258869B1 (en) * | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
EP2280021B1 (en) | 1999-06-29 | 2016-02-17 | MannKind Corporation | Pharmaceutical formulations comprising insulin complexed with a diketopiperazine |
SI1494732T1 (sl) | 2002-03-20 | 2008-08-31 | Mannking Corp | Inhalacijski aparat |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
US7820676B2 (en) | 2004-08-23 | 2010-10-26 | Mannkind Corporation | Diketopiperazine salts for drug delivery and related methods |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
CA2621806C (en) | 2005-09-14 | 2016-08-02 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
RU2403059C2 (ru) | 2006-02-22 | 2010-11-10 | Маннкайнд Корпорейшн | Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент |
CA2651855C (en) | 2006-05-30 | 2011-08-02 | Intarcia Therapeutics, Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
ES2402172T3 (es) * | 2007-04-23 | 2013-04-29 | Intarcia Therapeutics, Inc | Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos |
US8785396B2 (en) * | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
JP5694779B2 (ja) | 2008-01-09 | 2015-04-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体 |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
CA3086027C (en) | 2008-06-13 | 2022-05-17 | Mannkind Corporation | A dry powder inhaler and system for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
RU2470681C2 (ru) | 2008-06-20 | 2012-12-27 | Маннкайнд Корпорейшн | Интерактивное устройство и способ профилирования усилий при ингаляции в реальном масштабе времени |
TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
KR101760953B1 (ko) | 2008-09-04 | 2017-07-24 | 아밀린 파마슈티칼스, 엘엘씨. | 비-수성 담체를 이용한 서방성 제형물 |
NZ592113A (en) * | 2008-10-15 | 2012-04-27 | Intarcia Therapeutics Inc | Highly concentrated drug particles, formulations, suspensions and uses thereof |
AU2014268265B2 (en) * | 2008-10-15 | 2016-11-03 | Intarcia Therapeutics, Inc. | Highly concentrated drug particles, formulations, suspensions and uses thereof |
PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
US20100183876A1 (en) * | 2008-12-23 | 2010-07-22 | Hell Andre | Process for the Preparation of a Peptide Powder Form |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
EP2676695A3 (en) | 2009-03-11 | 2017-03-01 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
KR20210027546A (ko) | 2009-06-12 | 2021-03-10 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
KR101853606B1 (ko) * | 2009-07-06 | 2018-05-03 | 사노피-아벤티스 도이칠란트 게엠베하 | 메티오닌을 함유하는 수성 인슐린 제제 |
WO2011017335A1 (en) | 2009-08-03 | 2011-02-10 | Incube Labs, Llc | Swallowable capsule and method for stimulating incretin production within the intestinal tract |
AU2014280920B2 (en) * | 2009-09-28 | 2016-05-12 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
EP3323423B1 (en) * | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
PT2498801T (pt) * | 2009-11-13 | 2018-05-02 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendin-4(1-39)-lys6-nh2 e metionina |
US10029011B2 (en) * | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
US8759284B2 (en) | 2009-12-24 | 2014-06-24 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
CN102274182B (zh) * | 2010-06-13 | 2013-04-03 | 上海现代药物制剂工程研究中心有限公司 | 一种含有艾塞那肽的多囊脂质体及其制备方法和应用 |
RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
US20120046225A1 (en) * | 2010-07-19 | 2012-02-23 | The Regents Of The University Of Colorado, A Body Corporate | Stable glucagon formulations for the treatment of hypoglycemia |
SG187904A1 (en) | 2010-08-30 | 2013-04-30 | Sanofi Aventis Deutschland | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8809271B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US20140045754A1 (en) * | 2011-01-19 | 2014-02-13 | Joern Drustrup | Glp-1 compositions |
WO2012098188A1 (en) * | 2011-01-19 | 2012-07-26 | Novo Nordisk A/S | Glp-1 particles and compositions |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
EP2683364B1 (en) | 2011-03-10 | 2017-01-18 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
EP3225235B1 (en) * | 2011-03-10 | 2020-12-16 | Xeris Pharmaceuticals, Inc. | Stable peptide formulations for parenteral injection |
EP2694402B1 (en) | 2011-04-01 | 2017-03-22 | MannKind Corporation | Blister package for pharmaceutical cartridges |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
KR101983982B1 (ko) | 2011-08-29 | 2019-05-30 | 사노피-아벤티스 도이칠란트 게엠베하 | 2형 당뇨병 환자의 혈당 조절에 사용하기 위한 약제학적 병용물 |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
CN103945859A (zh) | 2011-10-24 | 2014-07-23 | 曼金德公司 | 用于治疗疼痛的方法和组合物 |
CN103930096B (zh) | 2011-10-31 | 2017-05-31 | Xeris药物公司 | 用于治疗糖尿病的制剂 |
US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
CN104619369B (zh) | 2012-07-12 | 2018-01-30 | 曼金德公司 | 干粉药物输送系统和方法 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
UA116553C2 (uk) | 2012-12-21 | 2018-04-10 | Санофі | Пептидна сполука - агоніст рецептора glp-1 i glp |
TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
JP6523247B2 (ja) | 2013-03-15 | 2019-05-29 | マンカインド コーポレイション | 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法 |
KR102321339B1 (ko) | 2013-07-18 | 2021-11-02 | 맨카인드 코포레이션 | 열-안정성 건조 분말 약제학적 조성물 및 방법 |
WO2015021064A1 (en) | 2013-08-05 | 2015-02-12 | Mannkind Corporation | Insufflation apparatus and methods |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/升糖素受體促效劑 |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
EP3091965A1 (en) | 2014-01-09 | 2016-11-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
MX2016008979A (es) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina. |
US9895423B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AU2015300944B2 (en) | 2014-08-06 | 2019-07-11 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
US10479868B2 (en) * | 2014-09-04 | 2019-11-19 | Nano Precision Medical, Inc. | Polymeric stabilizing formulations |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
NZ733670A (en) | 2014-12-12 | 2021-12-24 | Sanofi Aventis Deutschland | Insulin glargine/lixisenatide fixed ratio formulation |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
US10660937B2 (en) | 2015-05-22 | 2020-05-26 | The Board Of Trustees Of The Leland Stanford Junio | Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39) |
AU2016270984B2 (en) | 2015-06-03 | 2021-02-25 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
EP3307295A1 (en) * | 2015-06-10 | 2018-04-18 | Xeris Pharmaceuticals, Inc. | Use of low dose glucagon |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
US10653753B2 (en) | 2016-03-04 | 2020-05-19 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
KR20240037175A (ko) | 2016-05-16 | 2024-03-21 | 인타르시아 세라퓨틱스 인코포레이티드 | 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법 |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
EP3528836A1 (en) | 2016-10-20 | 2019-08-28 | Peptron, Inc. | Methods of delivering a neuroprotective polypeptide to the central nervous system |
WO2018094404A1 (en) | 2016-11-21 | 2018-05-24 | Eiger Biopharmaceuticals, Inc. | Buffered formulations of exendin (9-39) |
IL307966A (en) | 2017-01-03 | 2023-12-01 | Intarcia Therapeutics Inc | Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
JP7242060B2 (ja) * | 2017-04-10 | 2023-03-20 | 武漢格睿特科技有限公司 | 代謝系疾病の治療に用いられるポリペプチドおよびその組成物 |
KR20240036128A (ko) | 2017-06-02 | 2024-03-19 | 엑스에리스 파머수티클스, 인크. | 침전 방지 저분자 약물 제제 |
AU2018321157B2 (en) | 2017-08-24 | 2024-03-28 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
USD933219S1 (en) | 2018-07-13 | 2021-10-12 | Intarcia Therapeutics, Inc. | Implant removal tool and assembly |
EP3840710A4 (en) * | 2018-08-24 | 2022-05-18 | North Carolina State University | PATCHES WITH MICRONEEDLE ARRAYS WITH GLUCOSE SENSITIVE MATRIX FOR CLOSED CIRCUIT INSULIN DELIVERY |
US11617965B2 (en) | 2018-12-21 | 2023-04-04 | Novo Nordisk A/S | Process of spray drying of GLP-1 peptide |
EP3921082A4 (en) | 2019-02-05 | 2022-11-02 | Lindy Biosciences, Inc. | ISOLATED CELL CULTURE COMPONENTS AND METHODS OF ISOLATION THEREOF FROM LIQUID CELL CULTURE MEDIUM |
MX2021012354A (es) * | 2019-04-11 | 2021-10-22 | Scherer Technologies Llc R P | Formulación para suministro oral de proteínas, péptidos y moléculas pequeñas con poca permeabilidad. |
CN110732020B (zh) * | 2019-11-25 | 2023-10-03 | 江苏豪森药业集团有限公司 | 稳定的含有聚乙二醇洛塞那肽的药物制剂 |
IL294520A (en) | 2020-02-18 | 2022-09-01 | Novo Nordisk As | Pharmaceutical formulations |
CN115493919B (zh) * | 2022-11-21 | 2023-04-07 | 保定佳瑞源生物芯片有限公司 | 一种c肽和胰岛素检测试剂盒的校准品稀释液 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006017852A2 (en) * | 2004-08-12 | 2006-02-16 | Quest Pharmaceutical Services | Pharmaceutical compositions for controlled release delivery of biologically active compounds |
WO2006084139A2 (en) * | 2005-02-03 | 2006-08-10 | Intarcia Therapeutics, Inc. | An implantable interferon-containing device |
WO2006083761A2 (en) * | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
WO2006087354A2 (en) * | 2005-02-16 | 2006-08-24 | Novo Nordisk A/S | Insulinotropic agents conjugated with structurally well defined branched polymers |
WO2006111169A1 (en) * | 2005-04-21 | 2006-10-26 | Gastrotech Pharma A/S | Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug |
WO2006131730A1 (en) * | 2005-06-06 | 2006-12-14 | Camurus Ab | Glp-1 analogue formulations |
JP2007501812A (ja) * | 2003-08-08 | 2007-02-01 | ノボ ノルディスク アクティーゼルスカブ | ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用 |
JP6016733B2 (ja) * | 2007-04-23 | 2016-10-26 | インターシア セラピューティクス,インコーポレイティド | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
Family Cites Families (657)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR640907A (fr) | 1927-06-25 | 1928-07-24 | Limitateur de débit automatique | |
US2168437A (en) | 1935-04-10 | 1939-08-08 | Kenneth O Buercklin | Injection device |
US2110208A (en) | 1937-02-12 | 1938-03-08 | U S Standard Products Company | Antigen preparations |
US3025991A (en) | 1960-05-23 | 1962-03-20 | Carron Products Co | Bottle stopper |
NL137652C (ja) | 1962-07-11 | |||
GB1049104A (en) | 1963-05-11 | 1966-11-23 | Prodotti Antibiotici Spa | Pharmaceutical compositions for oral or parenteral administration comprising tetracycline antibiotics |
US3122162A (en) | 1963-06-20 | 1964-02-25 | Asa D Sands | Flow control device |
BE744162A (fr) | 1969-01-16 | 1970-06-15 | Fuji Photo Film Co Ltd | Procede d'encapsulage |
US3632768A (en) | 1969-10-02 | 1972-01-04 | Upjohn Co | Therapeutic composition and method for treating infections with actinospectacin |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
DE2010115A1 (de) | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Mikrogranulaten |
US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
US3732865A (en) | 1971-01-13 | 1973-05-15 | Alza Corp | Osmotic dispenser |
US4034756A (en) | 1971-01-13 | 1977-07-12 | Alza Corporation | Osmotically driven fluid dispenser |
US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
JPS523342B2 (ja) | 1972-01-26 | 1977-01-27 | ||
BE795516A (fr) | 1972-02-17 | 1973-08-16 | Ciba Geigy | Preparations de peptides huileuses et injectables et procede pour leur preparation |
US3797492A (en) | 1972-12-27 | 1974-03-19 | Alza Corp | Device for dispensing product with directional guidance member |
US3995632A (en) | 1973-05-04 | 1976-12-07 | Alza Corporation | Osmotic dispenser |
GB1413186A (en) | 1973-06-27 | 1975-11-12 | Toyo Jozo Kk | Process for encapsulation of medicaments |
DE2528516A1 (de) | 1974-07-05 | 1976-01-22 | Sandoz Ag | Neue galenische zubereitung |
JPS523653A (en) | 1975-06-27 | 1977-01-12 | Fuji Photo Film Co Ltd | Process for producing fine polymer particles |
US3987790A (en) | 1975-10-01 | 1976-10-26 | Alza Corporation | Osmotically driven fluid dispenser |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4078060A (en) | 1976-05-10 | 1978-03-07 | Richardson-Merrell Inc. | Method of inducing an estrogenic response |
US4111203A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
US4111202A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4203439A (en) | 1976-11-22 | 1980-05-20 | Alza Corporation | Osmotic system with volume amplifier for increasing amount of agent delivered therefrom |
US4111201A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for delivering selected beneficial agents having varying degrees of solubility |
USD258837S (en) | 1977-10-17 | 1981-04-07 | Gambro Dialysatoren Gmbh And Co. Kg | Dialyzer cartridge |
US4243030A (en) | 1978-08-18 | 1981-01-06 | Massachusetts Institute Of Technology | Implantable programmed microinfusion apparatus |
US4305927A (en) | 1979-02-05 | 1981-12-15 | Alza Corporation | Method for the management of intraocular pressure |
US4373527B1 (en) | 1979-04-27 | 1995-06-27 | Univ Johns Hopkins | Implantable programmable medication infusion system |
US4310516A (en) | 1980-02-01 | 1982-01-12 | Block Drug Company Inc. | Cosmetic and pharmaceutical vehicle thickened with solid emulsifier |
US4384975A (en) | 1980-06-13 | 1983-05-24 | Sandoz, Inc. | Process for preparation of microspheres |
AU546785B2 (en) | 1980-07-23 | 1985-09-19 | Commonwealth Of Australia, The | Open-loop controlled infusion of diabetics |
US4350271A (en) | 1980-08-22 | 1982-09-21 | Alza Corporation | Water absorbing fluid dispenser |
US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US4376118A (en) | 1980-10-06 | 1983-03-08 | Miles Laboratories, Inc. | Stable nonaqueous solution of tetracycline salt |
PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
US4340054A (en) | 1980-12-29 | 1982-07-20 | Alza Corporation | Dispenser for delivering fluids and solids |
US4455145A (en) | 1981-07-10 | 1984-06-19 | Alza Corporation | Dispensing device with internal drive |
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
EP0079143A3 (en) | 1981-10-20 | 1984-11-21 | Adnovum Ag | Pseudoplastic gel transfer |
DE3273597D1 (en) | 1981-11-28 | 1986-11-06 | Sunstar Kk | Pharmaceutical composition containing interferon in stable state |
US5004689A (en) | 1982-02-22 | 1991-04-02 | Biogen, Massachusetts | DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4455143A (en) | 1982-03-22 | 1984-06-19 | Alza Corporation | Osmotic device for dispensing two different medications |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
DE3220116A1 (de) | 1982-05-28 | 1983-12-01 | Dr. Karl Thomae Gmbh, 7950 Biberach | Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4753651A (en) | 1982-08-30 | 1988-06-28 | Alza Corporation | Self-driven pump |
US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4552561A (en) | 1982-12-23 | 1985-11-12 | Alza Corporation | Body mounted pump housing and pump assembly employing the same |
US4673405A (en) | 1983-03-04 | 1987-06-16 | Alza Corporation | Osmotic system with instant drug availability |
US4639244A (en) | 1983-05-03 | 1987-01-27 | Nabil I. Rizk | Implantable electrophoretic pump for ionic drugs and associated methods |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
DE3320583A1 (de) | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung |
JPS6058915A (ja) | 1983-09-12 | 1985-04-05 | Fujisawa Pharmaceut Co Ltd | 薬物含有脂質小胞体製剤 |
US4594108A (en) | 1983-09-19 | 1986-06-10 | The Dow Chemical Company | Highly pseudoplastic polymer solutions |
US5385738A (en) | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
US4923805A (en) | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
US5639639A (en) | 1983-11-02 | 1997-06-17 | Genzyme Corporation | Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof |
US4840896A (en) | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
MX9203641A (es) | 1983-12-16 | 1992-07-01 | Genentech Inc | Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion. |
US4851228A (en) | 1984-06-20 | 1989-07-25 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic |
US5231176A (en) | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
US5120832A (en) | 1984-08-27 | 1992-06-09 | Genentech, Inc. | Distinct family of human leukocyte interferons |
US4927687A (en) | 1984-10-01 | 1990-05-22 | Biotek, Inc. | Sustained release transdermal drug delivery composition |
US5411951A (en) | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
FI90990C (fi) | 1984-12-18 | 1994-04-25 | Boehringer Ingelheim Int | Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi |
US4655462A (en) | 1985-01-07 | 1987-04-07 | Peter J. Balsells | Canted coiled spring and seal |
JPS61189230A (ja) | 1985-02-19 | 1986-08-22 | Nippon Kayaku Co Ltd | エトポシド製剤 |
US4609374A (en) | 1985-04-22 | 1986-09-02 | Alza Corporation | Osmotic device comprising means for governing initial time of agent release therefrom |
US4885166A (en) | 1985-06-11 | 1989-12-05 | Ciba-Geigy Corporation | Hybrid interferons |
US4845196A (en) | 1985-06-24 | 1989-07-04 | G. D. Searle & Co. | Modified interferon gammas |
US4847079A (en) | 1985-07-29 | 1989-07-11 | Schering Corporation | Biologically stable interferon compositions comprising thimerosal |
IE59361B1 (en) | 1986-01-24 | 1994-02-09 | Akzo Nv | Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension |
DE3607835A1 (de) | 1986-03-10 | 1987-09-24 | Boehringer Ingelheim Int | Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung |
US4865845A (en) | 1986-03-21 | 1989-09-12 | Alza Corporation | Release rate adjustment of osmotic or diffusional delivery devices |
US4737437A (en) | 1986-03-27 | 1988-04-12 | East Shore Chemical Co. | Light sensitive diazo compound, composition and method of making the composition |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US7138486B2 (en) | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US4755180A (en) | 1986-06-16 | 1988-07-05 | Alza Corporation | Dosage form comprising solubility regulating member |
DE3636123A1 (de) | 1986-10-23 | 1988-05-05 | Rentschler Arzneimittel | Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten |
ZA878295B (en) | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
DE3642096A1 (de) | 1986-12-10 | 1988-06-16 | Boehringer Ingelheim Int | Pferde-(gamma)-interferon |
US5371089A (en) | 1987-02-26 | 1994-12-06 | Senetek, Plc | Method and composition for ameliorating the adverse effects of aging |
US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
JPH0720866B2 (ja) | 1987-05-15 | 1995-03-08 | 三生製薬株式会社 | エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤 |
US4940465A (en) | 1987-05-27 | 1990-07-10 | Felix Theeuwes | Dispenser comprising displaceable matrix with solid state properties |
US4892778A (en) | 1987-05-27 | 1990-01-09 | Alza Corporation | Juxtaposed laminated arrangement |
US4874388A (en) | 1987-06-25 | 1989-10-17 | Alza Corporation | Multi-layer delivery system |
US5938654A (en) | 1987-06-25 | 1999-08-17 | Alza Corporation | Osmotic device for delayed delivery of agent |
US5023088A (en) | 1987-06-25 | 1991-06-11 | Alza Corporation | Multi-unit delivery system |
US4915949A (en) | 1987-07-13 | 1990-04-10 | Alza Corporation | Dispenser with movable matrix comprising a plurality of tiny pills |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
DE19975054I2 (de) | 1987-08-08 | 2000-04-13 | Akzo Nobel Nv | Kontrazeptives Implantat |
US4915954A (en) | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
US5756450A (en) | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
US4886668A (en) | 1987-09-24 | 1989-12-12 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic pump |
GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
AU2810189A (en) | 1987-10-30 | 1989-05-23 | Stolle Research & Development Corporation | Low residual solvent microspheres and microencapsulation process |
US4917895A (en) | 1987-11-02 | 1990-04-17 | Alza Corporation | Transdermal drug delivery device |
US4964204A (en) | 1988-04-25 | 1990-10-23 | Peter J. Balsells | Method for making a garter-type axially-resilient coil spring |
US5072070A (en) | 1989-12-01 | 1991-12-10 | Peter J. Balsells | Device for sealing electromagnetic waves |
US5160122A (en) | 1990-03-20 | 1992-11-03 | Peter J. Balsells | Coil spring with an elastomer having a hollow coil cross section |
US5203849A (en) | 1990-03-20 | 1993-04-20 | Balsells Peter J | Canted coil spring in length filled with an elastomer |
US4907788A (en) | 1988-04-25 | 1990-03-13 | Peter J. Balsells | Dual concentric canted-coil spring apparatus |
US4915366A (en) | 1988-04-25 | 1990-04-10 | Peter J. Balsells | Outside back angle canted coil spring |
US5117066A (en) | 1988-04-25 | 1992-05-26 | Peter J. Balsells | Retaining and locking electromagnetic gasket |
US5079388A (en) | 1989-12-01 | 1992-01-07 | Peter J. Balsells | Gasket for sealing electromagnetic waves |
US4830344A (en) | 1988-04-25 | 1989-05-16 | Peter J. Balsells | Canted-coil spring with turn angle and seal |
US4934666A (en) | 1988-04-25 | 1990-06-19 | Peter J. Balsells | Coiled spring electromagnetic shielding gasket |
DE68909295T2 (de) | 1988-04-25 | 1994-05-11 | Peter J Balsells | In sich geschlossene ringförmige Schraubenfeder mit äusserem, rückwärtigem Neigungswinkel. |
US4974821A (en) | 1988-04-25 | 1990-12-04 | Peter J. Balsells | Canted-coil spring with major axis radial loading |
US4876781A (en) | 1988-04-25 | 1989-10-31 | Peter J. Balsells | Method of making a garter-type axially resilient coiled spring |
US4826144A (en) | 1988-04-25 | 1989-05-02 | Peter J. Balsells | Inside back angle canted coil spring |
US4961253A (en) | 1988-04-25 | 1990-10-09 | Peter J. Balsells | Manufacturing method for canted-coil spring with turn angle and seal |
US4893795A (en) | 1988-08-15 | 1990-01-16 | Peter J. Balsells | Radially loaded canted coiled spring with turn angle |
US5108078A (en) | 1988-04-25 | 1992-04-28 | Peter J. Balsells | Canted-coil spring loaded while in a cavity |
US5024842A (en) | 1988-04-28 | 1991-06-18 | Alza Corporation | Annealed coats |
US5006346A (en) | 1988-04-28 | 1991-04-09 | Alza Corporation | Delivery system |
US4931285A (en) | 1988-04-28 | 1990-06-05 | Alza Corporation | Aqueous based pharmaceutical coating composition for dosage forms |
US5160743A (en) | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
JP2827287B2 (ja) | 1988-07-05 | 1998-11-25 | 武田薬品工業株式会社 | 水溶性薬物含有徐放型マイクロカプセル |
JP2794022B2 (ja) | 1988-11-11 | 1998-09-03 | 三生製薬株式会社 | ブナゾシン或いはその塩類含有経皮適用製剤 |
US5110596A (en) | 1988-12-13 | 1992-05-05 | Alza Corporation | Delivery system comprising means for delivering agent to livestock |
US5057318A (en) | 1988-12-13 | 1991-10-15 | Alza Corporation | Delivery system for beneficial agent over a broad range of rates |
US5728088A (en) | 1988-12-13 | 1998-03-17 | Alza Corporation | Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals |
US5059423A (en) | 1988-12-13 | 1991-10-22 | Alza Corporation | Delivery system comprising biocompatible beneficial agent formulation |
US5034229A (en) | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
US4969884A (en) | 1988-12-28 | 1990-11-13 | Alza Corporation | Osmotically driven syringe |
US5234424A (en) | 1988-12-28 | 1993-08-10 | Alza Corporation | Osmotically driven syringe |
US4976966A (en) | 1988-12-29 | 1990-12-11 | Alza Corporation | Delayed release osmotically driven fluid dispenser |
IL92344A0 (en) | 1989-01-04 | 1990-07-26 | Gist Brocades Nv | Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules |
US5288479A (en) | 1989-01-17 | 1994-02-22 | Sterling Drug, Inc. | Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof |
US5705363A (en) | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
US5906816A (en) | 1995-03-16 | 1999-05-25 | University Of Florida | Method for treatment of autoimmune diseases |
US5219572A (en) | 1989-03-17 | 1993-06-15 | Pitman-Moore, Inc. | Controlled release delivery device for macromolecular proteins |
ES2062530T3 (es) | 1989-05-01 | 1994-12-16 | Alkermes Inc | Procedimiento para producir particulas pequeñas de moleculas biologicamente activas. |
US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
WO1990013361A1 (en) | 1989-05-04 | 1990-11-15 | Southern Research Institute | Improved encapsulation process and products therefrom |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5126142A (en) | 1989-07-18 | 1992-06-30 | Alza Corporation | Dispenser comprising ionophore |
US5439688A (en) | 1989-07-28 | 1995-08-08 | Debio Recherche Pharmaceutique S.A. | Process for preparing a pharmaceutical composition |
US5225205A (en) | 1989-07-28 | 1993-07-06 | Debiopharm S.A. | Pharmaceutical composition in the form of microparticles |
KR920702383A (ko) | 1989-08-28 | 1992-09-03 | 원본미기재 | 치료제의 방출을 조절하는데 유용한 생부식성 중합체 |
US5112614A (en) | 1989-09-14 | 1992-05-12 | Alza Corporation | Implantable delivery dispenser |
US5290558A (en) | 1989-09-21 | 1994-03-01 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
SE465950B (sv) | 1989-10-23 | 1991-11-25 | Medinvent Sa | Kombination av ett aggregat partikelformat, kristallint eller frystorkat laekemedel med en pseudoplastisk gel foer beredning av ett injicerbart preparat samt foerfarande foer dess framstaellning |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
DE69003805T2 (de) | 1989-11-13 | 1994-05-19 | Becton Dickinson France | Vorratsbehälter für einen bestandteil einer medikamentenlösung. |
JPH03236317A (ja) | 1989-12-06 | 1991-10-22 | Sansei Seiyaku Kk | ドパミン誘導体含有経皮用製剤 |
US5030216A (en) | 1989-12-15 | 1991-07-09 | Alza Corporation | Osmotically driven syringe |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
USD326718S (en) | 1989-12-26 | 1992-06-02 | Minnesota Mining And Manufacturing Co. | Blood sensor cassette |
US5213809A (en) | 1990-01-24 | 1993-05-25 | Alza Corporation | Delivery system comprising means for controlling internal pressure |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5223266A (en) | 1990-01-24 | 1993-06-29 | Alza Corporation | Long-term delivery device with early startup |
US5126147A (en) | 1990-02-08 | 1992-06-30 | Biosearch, Inc. | Sustained release dosage form |
US5478564A (en) | 1990-02-22 | 1995-12-26 | Teva Pharmaceutical Industries, Ltd. | Preparation of microparticles for controlled release of water-soluble substances |
US5122128A (en) | 1990-03-15 | 1992-06-16 | Alza Corporation | Orifice insert for a ruminal bolus |
US5120306A (en) | 1990-03-21 | 1992-06-09 | Gosselin Leon F | Direct delivery of anti-inflammatories to the proximal small bowel |
US5213810A (en) | 1990-03-30 | 1993-05-25 | American Cyanamid Company | Stable compositions for parenteral administration and method of making same |
US5207752A (en) | 1990-03-30 | 1993-05-04 | Alza Corporation | Iontophoretic drug delivery system with two-stage delivery profile |
US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
US5091188A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5290271A (en) | 1990-05-14 | 1994-03-01 | Jernberg Gary R | Surgical implant and method for controlled release of chemotherapeutic agents |
JPH0441153A (ja) | 1990-06-07 | 1992-02-12 | Daikin Ind Ltd | ビルトインモータの冷却装置 |
US5374620A (en) | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
US5234693A (en) | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5234692A (en) | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5180591A (en) | 1990-07-11 | 1993-01-19 | Alza Corporation | Delivery device with a protective sleeve |
US5234695A (en) | 1990-07-24 | 1993-08-10 | Eastman Kodak Company | Water dispersible vitamin E composition |
US5300302A (en) | 1990-10-04 | 1994-04-05 | Nestec S.A. | Pharmaceutical composition in gel form in a dispensing package |
US5529914A (en) | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
US5151093A (en) | 1990-10-29 | 1992-09-29 | Alza Corporation | Osmotically driven syringe with programmable agent delivery |
US5122377A (en) | 1990-11-19 | 1992-06-16 | A.H. Robins, Company, Incorporated | Oral delivery system for veterinary drugs |
IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
US5161806A (en) | 1990-12-17 | 1992-11-10 | Peter J. Balsells | Spring-loaded, hollow, elliptical ring seal |
GB9027422D0 (en) | 1990-12-18 | 1991-02-06 | Scras | Osmotically driven infusion device |
MX9200038A (es) | 1991-01-09 | 1992-11-01 | Alza Corp | Dispositivos biodegradables y composiciones para la liberacion por difusion de agentes. |
US5443459A (en) | 1991-01-30 | 1995-08-22 | Alza Corporation | Osmotic device for delayed delivery of agent |
NL9100160A (nl) | 1991-01-30 | 1992-08-17 | Texas Instruments Holland | Injector. |
US5861166A (en) | 1991-03-12 | 1999-01-19 | Alza Corporation | Delivery device providing beneficial agent stability |
US5113938A (en) | 1991-05-07 | 1992-05-19 | Clayton Charley H | Whipstock |
AU2154892A (en) | 1991-05-07 | 1992-12-21 | Dynagen, Inc. | A controlled, sustained release delivery system for treating drug dependency |
US5137727A (en) | 1991-06-12 | 1992-08-11 | Alza Corporation | Delivery device providing beneficial agent stability |
EP0520119A1 (de) | 1991-06-17 | 1992-12-30 | Spirig Ag Pharmazeutische Präparate | Neue orale Diclofenaczubereitung |
US5190765A (en) | 1991-06-27 | 1993-03-02 | Alza Corporation | Therapy delayed |
US5252338A (en) | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
HU222501B1 (hu) | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
DE4122217C2 (de) | 1991-07-04 | 1997-02-13 | Merz & Co Gmbh & Co | Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern |
US5288214A (en) | 1991-09-30 | 1994-02-22 | Toshio Fukuda | Micropump |
YU87892A (sh) | 1991-10-01 | 1995-12-04 | Eli Lilly And Company Lilly Corporate Center | Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu |
EP0664118B1 (en) | 1991-10-04 | 1999-08-25 | Yoshitomi Pharmaceutical Industries, Ltd. | Sustained-release tablet |
MX9205850A (es) | 1991-10-10 | 1993-06-01 | Alza Corp | Dispositivos de surtido osmotico de farmaco con materiales de pared hidrofobicos |
US5288502A (en) | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
US5236707A (en) | 1991-11-08 | 1993-08-17 | Dallas Biotherapeutics, Inc. | Stabilization of human interferon |
AU3136293A (en) | 1991-11-15 | 1993-06-15 | Isp Investments Inc. | Pharmaceutical tablet with pvp having an enhanced drug dissolution rate |
DE4137649C2 (de) | 1991-11-15 | 1997-11-20 | Gerhard Dingler | Bauelement |
US5200195A (en) | 1991-12-06 | 1993-04-06 | Alza Corporation | Process for improving dosage form delivery kinetics |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5223265A (en) | 1992-01-10 | 1993-06-29 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
US5658593A (en) | 1992-01-16 | 1997-08-19 | Coletica | Injectable compositions containing collagen microcapsules |
US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
US5308348A (en) | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
US5456679A (en) | 1992-02-18 | 1995-10-10 | Alza Corporation | Delivery devices with pulsatile effect |
US5209746A (en) | 1992-02-18 | 1993-05-11 | Alza Corporation | Osmotically driven delivery devices with pulsatile effect |
US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
JP3267972B2 (ja) | 1992-02-28 | 2002-03-25 | コラーゲン コーポレイション | 高濃度均質化コラーゲン組成物 |
US5221278A (en) | 1992-03-12 | 1993-06-22 | Alza Corporation | Osmotically driven delivery device with expandable orifice for pulsatile delivery effect |
US5656297A (en) | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
MX9301821A (es) | 1992-03-30 | 1994-03-31 | Alza Corp | Sistema de matriz polimerica biodegradable regulador de degradacion y metodo de tratamiento del mismo. |
WO1993019739A1 (en) | 1992-03-30 | 1993-10-14 | Alza Corporation | Viscous suspensions of controlled-release drug particles |
US6197346B1 (en) | 1992-04-24 | 2001-03-06 | Brown Universtiy Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
FR2690622B1 (fr) | 1992-04-29 | 1995-01-20 | Chronotec | Système de pompe à perfusion ambulatoire programmable. |
US5314685A (en) | 1992-05-11 | 1994-05-24 | Agouron Pharmaceuticals, Inc. | Anhydrous formulations for administering lipophilic agents |
US5711968A (en) | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
JP2651320B2 (ja) | 1992-07-16 | 1997-09-10 | 田辺製薬株式会社 | 徐放性マイクロスフェア製剤の製造方法 |
US5413672A (en) | 1992-07-22 | 1995-05-09 | Ngk Insulators, Ltd. | Method of etching sendust and method of pattern-etching sendust and chromium films |
US5512293A (en) | 1992-07-23 | 1996-04-30 | Alza Corporation | Oral sustained release drug delivery device |
US5609885A (en) | 1992-09-15 | 1997-03-11 | Alza Corporation | Osmotic membrane and delivery device |
GB9223146D0 (en) | 1992-11-05 | 1992-12-16 | Scherer Corp R P | Vented capsule |
EP0596161B1 (en) | 1992-11-06 | 1998-02-04 | Texas Instruments Incorporated | Apparatus for subcutaneous introduction of a needle |
CA2148823C (en) | 1992-11-17 | 1999-03-09 | Welfide Corporation | Sustained release microsphere preparation containing antipsychotic drug and production process thereof |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
EP0674506B1 (en) | 1992-12-02 | 2000-08-23 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
JP3698721B2 (ja) | 1993-02-23 | 2005-09-21 | ジェネンテク・インコーポレイテッド | 有機溶媒を用いて処理したポリペプチドの賦形剤安定化 |
US5368588A (en) | 1993-02-26 | 1994-11-29 | Bettinger; David S. | Parenteral fluid medication reservoir pump |
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
WO1994021262A1 (en) | 1993-03-17 | 1994-09-29 | Alza Corporation | Device for the transdermal administration of alprazolam |
US5514110A (en) | 1993-03-22 | 1996-05-07 | Teh; Eutiquio L. | Automatic flow control device |
NZ250844A (en) | 1993-04-07 | 1996-03-26 | Pfizer | Treatment of non-insulin dependant diabetes with peptides; composition |
US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
TW360548B (en) | 1993-04-08 | 1999-06-11 | Powderject Res Ltd | Products for therapeutic use |
NZ247516A (en) | 1993-04-28 | 1995-02-24 | Bernard Charles Sherman | Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5639477A (en) | 1993-06-23 | 1997-06-17 | Alza Corporation | Ruminal drug delivery device |
WO1995001167A2 (en) | 1993-06-25 | 1995-01-12 | Alza Corporation | Incorporating poly-n-vinyl amide in a transdermal system |
US5498255A (en) | 1993-08-17 | 1996-03-12 | Alza Corporation | Osmotic device for protracted pulsatile delivery of agent |
US5385887A (en) | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
JP2700141B2 (ja) | 1993-09-17 | 1998-01-19 | 富士化学工業株式会社 | リン酸水素カルシウム及びその製法並びにそれを用いた賦形剤 |
CA2167526A1 (en) | 1993-09-29 | 1995-04-06 | Lina Tormen Taskovich | Monoglyceride/lactate ester permeation enhancer |
US6913767B1 (en) | 1993-10-25 | 2005-07-05 | Genentech, Inc. | Compositions for microencapsulation of antigens for use as vaccines |
SI0729357T1 (en) | 1993-11-19 | 2005-06-30 | Janssen Pharmaceutica N.V. | Microencapsulated 1,2-benzazoles |
JPH09505308A (ja) | 1993-11-19 | 1997-05-27 | アルカーミズ・コントロールド・セラピューティクス・インコーポレイテッド・トゥー | 生物学的活性剤を含有する生分解性微粒子の製造 |
US5650173A (en) | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
JPH07196479A (ja) | 1994-01-04 | 1995-08-01 | Unitika Ltd | マイクロカプセルの製造法 |
USD358644S (en) | 1994-01-18 | 1995-05-23 | Bio Medic Data Systems, Inc. | Transponder implanter |
US6241734B1 (en) | 1998-08-14 | 2001-06-05 | Kyphon, Inc. | Systems and methods for placing materials into bone |
US5540665A (en) | 1994-01-31 | 1996-07-30 | Alza Corporation | Gas driven dispensing device and gas generating engine therefor |
EP0744939B1 (en) | 1994-02-04 | 2002-09-25 | Lipocore Holding AB | Bilayer preparations made from digalactosyldiacylglycerol containing galactolipid |
US5697975A (en) | 1994-02-09 | 1997-12-16 | The University Of Iowa Research Foundation | Human cerebral cortex neural prosthetic for tinnitus |
US5458888A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US6007805A (en) | 1994-03-07 | 1999-12-28 | Imperial College Of Science And Technology | Use of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver |
ZA953078B (en) | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
ES2183841T3 (es) | 1994-06-13 | 2003-04-01 | Alza Corp | Formas de dosificacion para administrar un farmasco en una formulacion lquidid. |
NL9401150A (nl) | 1994-07-12 | 1996-02-01 | Nederland Ptt | Werkwijze voor het aan een ontvangzijde aanbieden van een van een zendzijde afkomstig eerste aantal videosignalen, alsmede systeem, alsmede zender, alsmede netwerk, en alsmede ontvanger. |
EP0804155B1 (en) | 1994-07-13 | 2000-11-08 | Alza Corporation | Composition and method for enhancing transdermal electrotransport agent delivery |
US5633011A (en) | 1994-08-04 | 1997-05-27 | Alza Corporation | Progesterone replacement therapy |
US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5595759A (en) | 1994-11-10 | 1997-01-21 | Alza Corporation | Process for providing therapeutic composition |
AU708529B2 (en) | 1994-11-10 | 1999-08-05 | University Of Kentucky Research Foundation, The | Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body |
FR2731150B1 (fr) | 1995-03-03 | 1997-04-18 | Oreal | Utilisation de composes amphiphiles en tant qu'agent epaississant de milieux non aqueux |
US5962023A (en) | 1995-03-06 | 1999-10-05 | Ethicon, Inc. | Hydrogels containing absorbable polyoxaamides |
US5595751A (en) | 1995-03-06 | 1997-01-21 | Ethicon, Inc. | Absorbable polyoxaesters containing amines and/or amido groups |
US6403655B1 (en) | 1995-03-06 | 2002-06-11 | Ethicon, Inc. | Method of preventing adhesions with absorbable polyoxaesters |
US5698213A (en) | 1995-03-06 | 1997-12-16 | Ethicon, Inc. | Hydrogels of absorbable polyoxaesters |
US5597579A (en) | 1995-03-06 | 1997-01-28 | Ethicon, Inc. | Blends of absorbable polyoxaamides |
US5618552A (en) | 1995-03-06 | 1997-04-08 | Ethicon, Inc. | Absorbable polyoxaesters |
US6147168A (en) | 1995-03-06 | 2000-11-14 | Ethicon, Inc. | Copolymers of absorbable polyoxaesters |
US6100346A (en) | 1995-03-06 | 2000-08-08 | Ethicon, Inc. | Copolymers of polyoxaamides |
US5700583A (en) | 1995-03-06 | 1997-12-23 | Ethicon, Inc. | Hydrogels of absorbable polyoxaesters containing amines or amido groups |
US5859150A (en) | 1995-03-06 | 1999-01-12 | Ethicon, Inc. | Prepolymers of absorbable polyoxaesters |
US5464929A (en) | 1995-03-06 | 1995-11-07 | Ethicon, Inc. | Absorbable polyoxaesters |
US5607687A (en) | 1995-03-06 | 1997-03-04 | Ethicon, Inc. | Polymer blends containing absorbable polyoxaesters |
US5648088A (en) | 1995-03-06 | 1997-07-15 | Ethicon, Inc. | Blends of absorbable polyoxaesters containing amines and/or amide groups |
US5844017A (en) | 1995-03-06 | 1998-12-01 | Ethicon, Inc. | Prepolymers of absorbable polyoxaesters containing amines and/or amido groups |
US5542682A (en) | 1995-03-27 | 1996-08-06 | American Variseal | Slant coil spring and seal |
US5736159A (en) | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
CN1170596C (zh) | 1995-05-02 | 2004-10-13 | 大正制药株式会社 | 口服用组合物 |
US5939286A (en) | 1995-05-10 | 1999-08-17 | University Of Florida | Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them |
US5922253A (en) | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
US5882676A (en) | 1995-05-26 | 1999-03-16 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
US5718922A (en) | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
PT831826E (pt) | 1995-06-06 | 2003-02-28 | Hoffmann La Roche | Composicao farmaceutica que inclui um inibidor de proteinase e um monoglicerideo |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US7833543B2 (en) | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
US6572879B1 (en) | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
DE69625483T3 (de) | 1995-06-07 | 2012-05-10 | Ortho-Mcneil Pharmaceutical, Inc. | Transdermales pflaster zur verabreichung von 17-deacetyl norgestimat in kombination mit einem östrogen |
US5690952A (en) | 1995-06-07 | 1997-11-25 | Judy A. Magruder et al. | Implantable system for delivery of fluid-sensitive agents to animals |
US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
US5782396A (en) | 1995-08-28 | 1998-07-21 | United States Surgical Corporation | Surgical stapler |
US5906830A (en) | 1995-09-08 | 1999-05-25 | Cygnus, Inc. | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
US5942253A (en) | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
GB9521125D0 (en) | 1995-10-16 | 1995-12-20 | Unilever Plc | Cosmetic composition |
SE505146C2 (sv) | 1995-10-19 | 1997-06-30 | Biogram Ab | Partiklar för fördröjd frisättning |
US5766620A (en) | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
GB9521805D0 (en) | 1995-10-25 | 1996-01-03 | Cortecs Ltd | Solubilisation methods |
DE69626927T2 (de) | 1995-10-30 | 2003-11-20 | Oleoyl Estrone Developments S | Oleat Monoester von Estrogenen zur Behandlung von Fettleibigkeit |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
CA2329474C (en) | 1995-11-02 | 2002-02-26 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
CA2192773C (en) | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Production of sustained-release preparation for injection |
AUPN723395A0 (en) | 1995-12-19 | 1996-01-18 | Macnaught Medical Pty Limited | Lubrication methods |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
DE69624087T2 (de) | 1996-01-31 | 2003-06-05 | Sumitomo Bakelite Co | Verfahren zur Herstellung von in Epoxyharz eingekapselter Halbleitervorrichtung |
US6156331A (en) | 1996-02-02 | 2000-12-05 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6132420A (en) | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
WO1997028181A2 (en) | 1996-02-02 | 1997-08-07 | Rhomed Incorporated | Post-labeling stabilization of radiolabeled proteins and peptides |
US6261584B1 (en) | 1996-02-02 | 2001-07-17 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
EP1238657B1 (en) | 1996-02-02 | 2004-11-03 | ALZA Corporation | Sustained delivery of an active agent using an implantable system |
US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6245349B1 (en) | 1996-02-23 | 2001-06-12 | éLAN CORPORATION PLC | Drug delivery compositions suitable for intravenous injection |
WO1997031943A1 (en) | 1996-03-01 | 1997-09-04 | Novo Nordisk A/S | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
JPH09241153A (ja) | 1996-03-04 | 1997-09-16 | Q P Corp | 静脈注射用脂肪乳剤 |
IL126095A0 (en) | 1996-03-08 | 1999-05-09 | Zeneca Ltd | Azolobenzazepine derivatives as neurogically active agents |
WO1997033998A1 (en) | 1996-03-14 | 1997-09-18 | The Immune Response Corporation | Targeted delivery of genes encoding interferon |
US5703200A (en) | 1996-03-15 | 1997-12-30 | Ethicon, Inc. | Absorbable copolymers and blends of 6,6-dialkyl-1,4-dioxepan-2-one and its cyclic dimer |
US6190702B1 (en) | 1996-03-28 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase |
US5660858A (en) | 1996-04-03 | 1997-08-26 | Research Triangle Pharmaceuticals | Cyclosporin emulsions |
US6204022B1 (en) | 1996-04-12 | 2001-03-20 | Pepgen Corporation And University Of Florida | Low-toxicity human interferon-alpha analogs |
US6074673A (en) | 1996-04-22 | 2000-06-13 | Guillen; Manuel | Slow-release, self-absorbing, drug delivery system |
US5976109A (en) | 1996-04-30 | 1999-11-02 | Medtronic, Inc. | Apparatus for drug infusion implanted within a living body |
US5792477A (en) | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
EP0928136B1 (en) | 1996-06-05 | 2003-10-22 | Ashmont Holdings Limited | Injectable compositions |
DE59712555D1 (de) | 1996-06-05 | 2006-04-06 | Roche Diagnostics Gmbh | Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel |
DE29610419U1 (de) | 1996-06-14 | 1996-10-24 | Filtertek Sa | Schwerkraftinfusionsvorrichtung für medizinische Infusionen |
GB9613858D0 (en) | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
WO1998000152A1 (en) | 1996-07-03 | 1998-01-08 | Alza Corporation | Non-aqueous protic peptide formulations |
US5916582A (en) | 1996-07-03 | 1999-06-29 | Alza Corporation | Aqueous formulations of peptides |
ES2227707T3 (es) | 1996-07-15 | 2005-04-01 | Alza Corporation | Nuevas formulaciones para la administracion transdermica de acetato de fluoxetina y de maleato de fluoxetina. |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
US6458337B1 (en) | 1996-08-02 | 2002-10-01 | Dibra S.P.A | Diagnostic imaging contrast agent with improved in serum relaxivity |
ATE417622T1 (de) | 1996-08-08 | 2009-01-15 | Amylin Pharmaceuticals Inc | Regulation gastrointestinaler beweglichkeit |
WO1998007412A1 (en) | 1996-08-21 | 1998-02-26 | Alkermes Controlled Therapeutics, Inc. | Controlled release microparticles with a hydrophobic material |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US5984890A (en) | 1996-09-27 | 1999-11-16 | American Home Products Corporation | Medical device for the placement of solid materials |
IN184589B (ja) | 1996-10-16 | 2000-09-09 | Alza Corp | |
DK0934078T3 (da) | 1996-10-24 | 2003-04-14 | Alza Corp | Permeabilitetsfremmere til transdermal administrering af aktivstoffer, anordninger og fremgangsmåde til fremstilling deraf |
US5817129A (en) | 1996-10-31 | 1998-10-06 | Ethicon, Inc. | Process and apparatus for coating surgical sutures |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
DE19646392A1 (de) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
US5928666A (en) | 1996-11-12 | 1999-07-27 | Cygnus Inc. | Crystalline form of estradiol and pharmaceutical formulations comprising same |
ATE245042T1 (de) | 1996-11-15 | 2003-08-15 | Alza Corp | Osmotisches verabreichungssystem und methode zur leistungserhöhung und verbesserung der initialwirkung von osmotischen verabreichungssystemen |
DE69735384T2 (de) | 1996-12-20 | 2006-08-10 | Alza Corp., Mountain View | Gelzusammensetzungen und verfahren |
GB9626513D0 (en) | 1996-12-20 | 1997-02-05 | Bioglan Ireland R & D Ltd | A pharmaceutical composition |
EP1629849B2 (en) | 1997-01-07 | 2017-10-04 | Amylin Pharmaceuticals, LLC | Pharmaceutical compositions comprising exendins and agonists thereof |
JP2001511128A (ja) | 1997-01-28 | 2001-08-07 | ファルマシア・アンド・アップジョン・カンパニー | 水不溶性ポルフィリンの脂質錯体の凍結乾燥物 |
US5945126A (en) | 1997-02-13 | 1999-08-31 | Oakwood Laboratories L.L.C. | Continuous microsphere process |
ZA981610B (en) | 1997-03-24 | 1999-08-26 | Alza Corp | Self adjustable exit port. |
US5874388A (en) | 1997-04-02 | 1999-02-23 | Dow Corning Corporation | Lubricant composition for disc brake caliper pin and a disc brake asembly containing the lubricant |
US6127520A (en) | 1997-04-15 | 2000-10-03 | Regents Of The University Of Michigan | Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles |
CA2286052A1 (en) | 1997-04-17 | 1998-10-29 | Lise Sylvest Nielsen | A novel bioadhesive drug delivery system based on liquid crystals |
AR012448A1 (es) | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
JP2001523103A (ja) | 1997-04-28 | 2001-11-20 | ローヌ−プーラン・ロレ・エス・アー | 腫瘍治療用血管形成アンタゴニストのアデノウイルスによる腫瘍内送達 |
US20020039594A1 (en) | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
US6663899B2 (en) | 1997-06-13 | 2003-12-16 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6113947A (en) | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
SI9700186B (sl) | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
MY125870A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system flow modulator apparatus and method |
MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
GB9718986D0 (en) | 1997-09-09 | 1997-11-12 | Danbiosyst Uk | Controlled release microsphere delivery system |
US6172046B1 (en) | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
EA003665B1 (ru) | 1997-09-29 | 2003-08-28 | Нектар Терапьютикс | Перфорированные микрочастицы и способ их использования |
JPH11100353A (ja) | 1997-09-29 | 1999-04-13 | Esupo Kk | 精製・脱臭液状エステルワックスとその組成物 |
US6133429A (en) | 1997-10-03 | 2000-10-17 | Becton Dickinson And Company | Chromophores useful for the preparation of novel tandem conjugates |
ATE383867T1 (de) | 1997-11-14 | 2008-02-15 | Amylin Pharmaceuticals Inc | Neuartige exendin agonisten |
JP2001526033A (ja) | 1997-12-08 | 2001-12-18 | ジェネンテク・インコーポレイテッド | ヒトインターフェロン−イプシロンというi型インターフェロン |
US6368612B1 (en) | 1997-12-12 | 2002-04-09 | Biohybrid Technologies Llc | Devices for cloaking transplanted cells |
CN100388916C (zh) | 1997-12-22 | 2008-05-21 | 阿尔扎有限公司 | 用于控释药物传递装置的速率控制膜 |
JP4173635B2 (ja) | 1997-12-29 | 2008-10-29 | インターシア セラピューティクス,インコーポレイティド | 膜プラグ保持機構を有する浸透供給装置 |
DK1300129T3 (da) | 1997-12-29 | 2005-06-20 | Alza Corp | Implantathætteglas |
PT1300174E (pt) | 1997-12-29 | 2005-07-29 | Alza Corp | ''kit'' de introducao de implante |
ES2378675T3 (es) | 1997-12-30 | 2012-04-16 | Intarcia Therapeutics, Inc | Sistema de suministro de un agente beneficioso con una membrana obturadora |
US20040024068A1 (en) | 1998-01-23 | 2004-02-05 | Trustees Of Tufts College | Antimicrobial compounds |
IT1298575B1 (it) | 1998-02-06 | 2000-01-12 | Vectorpharma Int | Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di |
US6017545A (en) | 1998-02-10 | 2000-01-25 | Modi; Pankaj | Mixed micellar delivery system and method of preparation |
WO1999040788A1 (en) | 1998-02-13 | 1999-08-19 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
US6703359B1 (en) | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
USD408917S (en) | 1998-02-26 | 1999-04-27 | Minnesota Mining And Manufacturing Company | Membrane support structure of a flow through cell for blood gas measurement |
US6224577B1 (en) | 1998-03-02 | 2001-05-01 | Medrad, Inc. | Syringes and plungers for use therein |
US6056718A (en) | 1998-03-04 | 2000-05-02 | Minimed Inc. | Medication infusion set |
US6245357B1 (en) | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
US6183461B1 (en) | 1998-03-11 | 2001-02-06 | Situs Corporation | Method for delivering a medication |
WO1999046332A1 (fr) | 1998-03-12 | 1999-09-16 | Daicel Chemical Industries, Ltd. | Composition de resine contenant de la lactone, objet moule dans cette composition, et film |
US6029361A (en) | 1998-03-25 | 2000-02-29 | Ultratech Stepper, Inc. | Air-guage nozzle probe structure for microlithographic image focusing |
US6074660A (en) | 1998-04-20 | 2000-06-13 | Ethicon, Inc. | Absorbable polyoxaesters containing amines and/ or amido groups |
TW586944B (en) | 1998-05-29 | 2004-05-11 | Sumitomo Pharma | Controlled release agent having a multi-layer structure |
US8626302B2 (en) | 1998-06-03 | 2014-01-07 | Spr Therapeutics, Llc | Systems and methods to place one or more leads in muscle for providing electrical stimulation to treat pain |
CZ294848B6 (cs) | 1998-06-12 | 2005-03-16 | Amylin Pharmaceuticals, Inc. | Glukagonu podobný peptid-1 zlepšuje odpověď ß-buněk na glukózu u subjektů se zhoršenou tolerancí glukózy |
US6277413B1 (en) | 1998-07-17 | 2001-08-21 | Skyepharma, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
US6472512B1 (en) | 1998-07-21 | 2002-10-29 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
US7390637B2 (en) | 1998-07-21 | 2008-06-24 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
US6270700B1 (en) | 1998-07-23 | 2001-08-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Encapsulation of water soluble peptides |
US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
US6551613B1 (en) | 1998-09-08 | 2003-04-22 | Alza Corporation | Dosage form comprising therapeutic formulation |
US6174547B1 (en) | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
EP1112060B1 (en) | 1998-09-09 | 2005-12-07 | ALZA Corporation | Dosage form comprising liquid formulation |
US6248112B1 (en) | 1998-09-30 | 2001-06-19 | C. R. Bard, Inc. | Implant delivery system |
US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
RU2246295C2 (ru) | 1998-11-02 | 2005-02-20 | Элзэ Копэрейшн | Лекарственная форма c постоянной скоростью высвобождения лекарственного вещества, ядро лекарственной формы и способ обеспечения облегченного высвобождения лекарственного вещества из лекарственной формы |
WO2000029206A1 (en) | 1998-11-13 | 2000-05-25 | Sensor Technologies Inc. | Monodisperse preparations useful with implanted devices |
US20030060425A1 (en) | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
JP3702181B2 (ja) | 1998-12-07 | 2005-10-05 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Glp−1の類似体 |
PT1140012E (pt) | 1998-12-17 | 2004-05-31 | Alza Corp | Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas |
HUP0104756A3 (en) | 1998-12-23 | 2006-04-28 | Amgen Inc Thousand Oaks | Polyol/oil suspensions for the sustained release of proteins |
US6433144B1 (en) | 1999-01-12 | 2002-08-13 | Viragen, Inc. | Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods |
NZ512671A (en) | 1998-12-31 | 2003-12-19 | Alza Corp | Osmotic delivery system having space efficient piston |
WO2000039280A2 (en) | 1998-12-31 | 2000-07-06 | Viragen, Inc. | Leukocyte-derived interferon preparations |
WO2000040273A2 (en) | 1999-01-08 | 2000-07-13 | Vical Incorporated | Treatment of viral diseases using an interferon omega expressing polynucleotide |
US6703225B1 (en) | 1999-01-12 | 2004-03-09 | Sumitomo Pharmaceuticals Company, Limited | Interferon-α |
US7399489B2 (en) | 1999-01-14 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Exendin analog formulations |
KR100675711B1 (ko) | 1999-01-14 | 2007-02-01 | 아밀린 파마슈티칼스, 인크. | 신규 엑센딘 아고니스트 제제 및 이의 투여 방법 |
AU770712B2 (en) | 1999-01-14 | 2004-02-26 | Amylin Pharmaceuticals, Inc. | Methods for glucagon suppression |
HUP0200202A3 (en) * | 1999-02-08 | 2009-08-28 | Alza Corp | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US6451974B1 (en) | 1999-03-17 | 2002-09-17 | Novo Nordisk A/S | Method of acylating peptides and novel acylating agents |
US6835194B2 (en) | 1999-03-18 | 2004-12-28 | Durect Corporation | Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners |
US6541021B1 (en) | 1999-03-18 | 2003-04-01 | Durect Corporation | Devices and methods for pain management |
AU773556B2 (en) | 1999-04-05 | 2004-05-27 | Mannkind Corporation | Methods for fine powder formation |
GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
BR0009840A (pt) | 1999-04-19 | 2002-01-08 | Schering Corp | Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes |
US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US6291013B1 (en) | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
TR200103188T2 (tr) | 1999-05-07 | 2002-04-22 | Pharmasol Gmbh | Sıvı ve katı lipit karışımları temelli lipid parçacıklar. |
US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
AU754770B2 (en) | 1999-05-17 | 2002-11-21 | Conjuchem Biotechnologies Inc. | Long lasting insulinotropic peptides |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
CA2375914A1 (en) | 1999-06-04 | 2000-12-14 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
CA2372994C (en) | 1999-06-04 | 2010-03-23 | Alza Corporation | Implantable gel compositions and method of manufacture |
US20030059376A1 (en) | 1999-06-04 | 2003-03-27 | Libbey Miles A. | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
US20010040326A1 (en) | 1999-06-14 | 2001-11-15 | Lord Corporation | Resilient member with deformed element and method of forming same |
US6833256B1 (en) | 1999-06-22 | 2004-12-21 | University Of Maryland | Interferon tau mutants and methods for making them |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
SE9903236D0 (sv) | 1999-09-10 | 1999-09-10 | Astra Ab | Method to obtain microparticles |
US6284283B1 (en) | 1999-10-21 | 2001-09-04 | Alkermes Controlled Therapeutics, Inc. | Method of producing sub-micron particles of biologically active agents and uses thereof |
US6436091B1 (en) | 1999-11-16 | 2002-08-20 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
WO2001043528A2 (en) | 1999-12-17 | 2001-06-21 | Durect Corporation | Devices and methods in intracerebrospinal delivery of morphine-6-glucuronide |
WO2001045675A2 (en) | 1999-12-21 | 2001-06-28 | Alza Corporation | Valve for osmotic devices |
US6498193B2 (en) | 1999-12-22 | 2002-12-24 | Trustees Of Dartmouth College | Treatment for complications of type 2 diabetes |
US6283949B1 (en) | 1999-12-27 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Refillable implantable drug delivery pump |
US6572890B2 (en) | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
US6472060B1 (en) | 2000-01-19 | 2002-10-29 | Seco Tools Ab | Coated body with nanocrystalline CVD coating for enhanced edge toughness and reduced friction |
US6844321B2 (en) | 2000-01-31 | 2005-01-18 | Novo Nordisk A/S | Crystallization of a GLP-1 analogue |
US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
US6471688B1 (en) | 2000-02-15 | 2002-10-29 | Microsolutions, Inc. | Osmotic pump drug delivery systems and methods |
US6464688B1 (en) | 2000-02-15 | 2002-10-15 | Microsolutions, Inc. | Osmotic pump delivery system with flexible drug compartment |
KR20030009389A (ko) | 2000-03-14 | 2003-01-29 | 브루카드 괴케 | 유문동-유문-십이지장 운동성에 대한 글루카곤 유사펩티드-1 (7-36)의 효과 |
US20030211974A1 (en) | 2000-03-21 | 2003-11-13 | Brodbeck Kevin J. | Gel composition and methods |
US8574146B2 (en) | 2000-04-14 | 2013-11-05 | Attenuex Technologies, Inc. | Implant with high vapor pressure medium |
ATE309822T1 (de) | 2000-04-19 | 2005-12-15 | Genentech Inc | Formulierungen mit verzögerter freisetzung enthaltend wachstumshormon |
US6875748B2 (en) | 2000-04-21 | 2005-04-05 | Vical Incorporated | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
AU6323001A (en) | 2000-05-19 | 2001-12-03 | Bionebraska Inc | Treatment of acute coronary syndrome with glp-1 |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
ATE346093T1 (de) | 2000-06-16 | 2006-12-15 | Lilly Co Eli | Analoge des glucagon ähnlichen peptid-1 |
US6479065B2 (en) | 2000-08-10 | 2002-11-12 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
AU2001296770A1 (en) | 2000-10-06 | 2002-04-15 | Durect Corporation | Devices and methods for management of inflammation |
AU2587002A (en) | 2000-11-03 | 2002-05-15 | Biomedicines Inc | Method for short-term and long-term drug dosimetry |
EP1335704A2 (en) | 2000-11-16 | 2003-08-20 | Durect Corporation | Implant dosage form and use thereof for the delivery of a cholesterol lowering agent |
US20050070883A1 (en) | 2000-11-29 | 2005-03-31 | Brown James E | Devices and methods for controlled delivery from a drug delivery device |
EA005584B1 (ru) | 2000-12-07 | 2005-04-28 | Эли Лилли Энд Компани | Слитые белки glp-1 |
US20020165286A1 (en) | 2000-12-08 | 2002-11-07 | Hanne Hedeman | Dermal anti-inflammatory composition |
EP1390061A2 (en) | 2000-12-13 | 2004-02-25 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
AU2002228608A1 (en) | 2000-12-13 | 2002-06-24 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
ATE450269T1 (de) | 2000-12-14 | 2009-12-15 | Amylin Pharmaceuticals Inc | Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten |
AU2002232824A1 (en) | 2000-12-21 | 2002-07-01 | Inhale Therapeutic Systems, Inc. | Induced phase transition method for the production of microparticles containing hydrophobic active agents |
IN188924B (ja) | 2001-03-01 | 2002-11-23 | Bharat Serums & Vaccines Ltd | |
CA2440387A1 (en) | 2001-03-23 | 2002-10-03 | Durect Corporation | Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space |
US6632217B2 (en) | 2001-04-19 | 2003-10-14 | Microsolutions, Inc. | Implantable osmotic pump |
US7144863B2 (en) | 2001-06-01 | 2006-12-05 | Eli Lilly And Company | GLP-1 formulations with protracted time action |
US6514517B2 (en) | 2001-06-20 | 2003-02-04 | Ethicon, Inc. | Antimicrobial coatings for medical devices |
PT1397155E (pt) | 2001-06-21 | 2015-12-07 | Genentech Inc | Formulação de libertação sustentada |
ATE478656T1 (de) | 2001-06-22 | 2010-09-15 | Univ Johns Hopkins Med | Biologisch abbaubare polymerzusammensetzungen, zusammensetzungen und damit in beziehung stehende verwendungen |
US7163688B2 (en) | 2001-06-22 | 2007-01-16 | Alza Corporation | Osmotic implant with membrane and membrane retention means |
ATE361758T1 (de) | 2001-06-22 | 2007-06-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer |
US20030138403A1 (en) | 2001-06-29 | 2003-07-24 | Maxygen Aps | Interferon formulations |
EP1416953A4 (en) | 2001-07-20 | 2005-11-09 | Intermune Inc | METHOD FOR THE TREATMENT OF LIVER FIBROSIS |
JP2005501058A (ja) | 2001-07-31 | 2005-01-13 | ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ | Glp−1、exendin−4、そのペプチド・アナログ及びその使用 |
CA2458371A1 (en) * | 2001-08-23 | 2003-03-06 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
JP2005502426A (ja) | 2001-09-14 | 2005-01-27 | フランシス ジェイ マーティン | 治療剤の徐放のための微細加工ナノ細孔デバイス |
DE60233811D1 (de) | 2001-09-17 | 2009-11-05 | Durect Corp | Vorrichtung und verfahren zur genauen abgabe eines wirkstoffs |
DE60230818D1 (de) | 2001-09-24 | 2009-02-26 | Imp Innovations Ltd | Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit |
WO2003030923A1 (en) | 2001-10-05 | 2003-04-17 | Intermune, Inc. | Method of treating hepatitis virus infection with a multiphasic interferon delivery profile |
US7041646B2 (en) | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
EP2226043B1 (en) | 2001-10-24 | 2014-12-31 | MED-EL Elektromedizinische Geräte GmbH | Implantable fluid delivery apparatus and implantable electrode |
US20040142902A1 (en) | 2001-11-08 | 2004-07-22 | Struijker- Boudier Harry A.J. | Implant dosage form and use thereof for the delivery of a cholosterol lowering agent |
US20030143197A1 (en) | 2001-11-09 | 2003-07-31 | Moran S. Mark | Method for treating diseases with omega interferon |
NZ533435A (en) | 2001-11-14 | 2007-10-26 | Alza Corp | Injectable depot compositions and uses thereof |
ATE502621T1 (de) | 2001-11-14 | 2011-04-15 | Durect Corp | Katheterinjizierbare depotzusammensetzungen und deren verwendung |
BR0206469A (pt) | 2001-11-14 | 2004-01-13 | Alza Corp | Composição injetável para depósito |
NZ533642A (en) | 2001-11-21 | 2006-12-22 | Alza Corp | Osmotic delivery device having a two-way valve and dynamically self-adjusting flow channel |
DE10159217A1 (de) | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
US20030108608A1 (en) | 2001-12-12 | 2003-06-12 | Erik Laridon | Thermoplastic articles comprising silver-containing antimicrobials and high amounts of carboxylic acid salts for increased surface-available silver |
US20030232078A1 (en) | 2001-12-19 | 2003-12-18 | Dong Liang C. | Formulation & dosage form for the controlled delivery of therapeutic agents |
WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
US7105489B2 (en) | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
AU2003217367B2 (en) | 2002-02-08 | 2005-09-08 | Alkermes Controlled Therapeutics, Inc. | Polymer-based compositions for sustained release |
US7635463B2 (en) | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
US20050260259A1 (en) | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
ATE494010T1 (de) | 2002-02-27 | 2011-01-15 | Pharmain Corp | Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung |
GB0204722D0 (en) | 2002-02-28 | 2002-04-17 | Norferm Da | Method |
GB2386066A (en) | 2002-02-28 | 2003-09-10 | Norbrook Lab Ltd | Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species |
JP2006512102A (ja) | 2002-04-11 | 2006-04-13 | メディミューン・ヴァクシンズ・インコーポレーテッド | 噴霧乾燥による生物活性材料の防腐 |
MXPA04011875A (es) | 2002-05-31 | 2005-03-31 | Titan Pharmaceuticals Inc | Dispositivo polimerico implantable para liberacion sostenida de buprenorfina. |
EP1536767B1 (en) | 2002-06-17 | 2007-08-08 | Alza Corporation | Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
BR0312429A (pt) | 2002-06-26 | 2005-04-19 | Alza Corp | Pistão de deformidade mìnima e de volume eficiente para sistemas de distribuição de drogas por osmose |
US7177526B2 (en) | 2002-06-28 | 2007-02-13 | Intel Corporation | System and method for improving audio during post-production of video recordings |
KR20050083605A (ko) | 2002-07-31 | 2005-08-26 | 알자 코포레이션 | 주사 가능한 다원성 중합체 데포트 조성물 및 이의 용도 |
MXPA05001242A (es) | 2002-07-31 | 2005-06-08 | Alza Corp | Composiciones de deposito inyectable y usos de las mismas. |
US20080260838A1 (en) | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
US20040229814A1 (en) * | 2002-08-28 | 2004-11-18 | James Dillon | Methods and compositions for protecting against cataract development associated with vitrectomies |
US20060084922A1 (en) | 2002-09-04 | 2006-04-20 | Ruark Botha | Device for securing a blood vessel cannula to a body |
WO2004035762A2 (en) | 2002-10-17 | 2004-04-29 | Alkermes Controlled Therapeutics, Inc. Ii | Microencapsulation and sustained release of biologically active polypeptides |
JP2006505562A (ja) | 2002-10-17 | 2006-02-16 | アルカーメス コントロールド セラピューティクス,インコーポレイテッド | 持続放出組成物の放出プロフィールの調節方法 |
CA2501677A1 (en) | 2002-10-22 | 2004-05-06 | Waratah Pharmaceuticals, Inc. | Treatment of diabetes |
ATE418323T1 (de) | 2002-11-06 | 2009-01-15 | Alza Corp | Depot-formulierungen mit verzögerter freisetzung |
US6969702B2 (en) | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
US7014636B2 (en) | 2002-11-21 | 2006-03-21 | Alza Corporation | Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel |
US7790681B2 (en) | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
US20040224903A1 (en) | 2002-12-19 | 2004-11-11 | Stephen Berry | Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device |
US7731947B2 (en) * | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
JP2004238392A (ja) | 2003-01-14 | 2004-08-26 | Nipro Corp | 安定化された蛋白質性製剤 |
WO2004075349A2 (en) | 2003-02-18 | 2004-09-02 | Medconx, Inc. | Male medical device electrical connector with engineered friction fit |
CA2520766A1 (en) | 2003-03-31 | 2004-10-21 | Alza Corporation | Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
NZ542779A (en) | 2003-03-31 | 2009-02-28 | Intarcia Therapeutics Inc | Osmotic pump with means for dissipating internal pressure by allowing osmotic material to be ejected from the container above a set internal pressure |
TW200505500A (en) | 2003-03-31 | 2005-02-16 | Alza Corp | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
WO2004103342A2 (en) | 2003-05-16 | 2004-12-02 | Alkermes Controlled Therapeutics, Inc. | Injectable sustained release compositions |
CA2519742A1 (en) | 2003-05-16 | 2004-11-25 | Blue Membranes Gmbh | Medical implants comprising biocompatible coatings |
EP1631308B1 (en) | 2003-05-30 | 2013-07-31 | Amylin Pharmaceuticals, LLC | Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
MXPA05013003A (es) | 2003-05-30 | 2006-03-17 | Alza Corp | Composiciones de deposito elastomerico implantables, usos de las mismas y metodo para elaboracion. |
EP2292254A3 (en) | 2003-06-03 | 2011-12-14 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
US8491571B2 (en) | 2003-06-12 | 2013-07-23 | Cordis Corporation | Orifice device having multiple channels with varying flow rates for drug delivery |
US7454765B2 (en) | 2003-07-09 | 2008-11-18 | Samsung Electronics Co., Ltd. | Optical disc drive |
US7205409B2 (en) | 2003-09-04 | 2007-04-17 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
US7098243B2 (en) * | 2003-09-16 | 2006-08-29 | Kemin Pharma Europe B.V.B.A. | Bicyclic carbohydrates as antiviral bioactives for the treatment of infections caused by the alphaherpesvirinae HSV-1 and HSV-2 |
US9005244B2 (en) | 2003-09-30 | 2015-04-14 | Ethicon, Inc. | Tissue approximation device |
JP2007507513A (ja) | 2003-09-30 | 2007-03-29 | アルザ・コーポレーション | 上昇傾向のレリース特性を生ずる浸透圧駆動活性剤供給装置 |
RU2006118808A (ru) | 2003-10-31 | 2007-12-10 | Алза Корпорейшн (Us) | Осмотический насос с самоудерживающейся, выполненной с возможностью быстрого пуска мембранной пробкой |
AU2004289218A1 (en) | 2003-11-06 | 2005-05-26 | Alza Corporation | Modular imbibition rate reducer for use with implantable osmotic pump |
US20050281879A1 (en) | 2003-11-14 | 2005-12-22 | Guohua Chen | Excipients in drug delivery vehicles |
US20050106214A1 (en) | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
US20050118206A1 (en) | 2003-11-14 | 2005-06-02 | Luk Andrew S. | Surfactant-based gel as an injectable, sustained drug delivery vehicle |
US7780973B2 (en) | 2003-12-15 | 2010-08-24 | Ethicon Endo-Surgery, Inc. | Method and device for minimally invasive implantation of biomaterial |
US20050216087A1 (en) | 2004-01-05 | 2005-09-29 | St. Francis Medical Technologies, Inc. | Disk repair structures for positioning disk repair material |
US20050175701A1 (en) | 2004-02-10 | 2005-08-11 | Alza Corporation | Capillary moderator for osmotic delivery system |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
CN1961000B (zh) | 2004-02-11 | 2011-05-04 | 安米林药品公司 | 具有可选择特性的杂合多肽 |
US7456254B2 (en) | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
EA200601904A1 (ru) | 2004-04-15 | 2007-02-27 | Алкермес, Инк. | Система отсроченного высвобождения лекарственного средства на основе полимеров |
US20050266087A1 (en) | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
WO2006000567A2 (en) | 2004-06-28 | 2006-01-05 | Novo Nordisk A/S | Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function |
US7772182B2 (en) | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
GB2434189B (en) | 2004-08-18 | 2009-04-01 | Waters Investments Ltd | Defined leak path for high pressure seal |
US8268791B2 (en) | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
US7442682B2 (en) * | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
CN101094689B (zh) | 2004-11-01 | 2013-06-12 | 安米林药品有限责任公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
US7575579B2 (en) | 2004-11-18 | 2009-08-18 | Union Surgical, Llc | Drill guide tissue protector |
US20060141040A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
US20060142234A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
EP1841448A2 (en) * | 2004-12-30 | 2007-10-10 | Diakine Therapeutics, Inc. | Pharmaceutical compositions and methods for restoring beta-cell mass and function |
MX2007008881A (es) | 2005-01-24 | 2007-08-14 | Organon Nv | Aplicador para insertar un implante. |
EP1843783B1 (en) * | 2005-01-25 | 2012-05-30 | MicroCHIPS, Inc. | Control of drug release by transient modification of local microenvironments |
US20060216242A1 (en) | 2005-02-03 | 2006-09-28 | Rohloff Catherine M | Suspending vehicles and pharmaceutical suspensions for drug dosage forms |
US20070032420A1 (en) | 2005-02-09 | 2007-02-08 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
US8404637B2 (en) | 2005-02-11 | 2013-03-26 | Amylin Pharmaceuticals, Llc | GIP analog and hybrid polypeptides with selectable properties |
GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
US7959938B2 (en) | 2005-03-15 | 2011-06-14 | Intarcia Therapeutics, Inc. | Polyoxaester suspending vehicles for use with implantable delivery systems |
ES2330671T3 (es) | 2005-03-31 | 2009-12-14 | Amylin Pharmaceuticals, Inc. | Amilina y agonistas de amilina para el tratamiento de enfermedades y trastornos psiquiatricos. |
EP1909824B1 (en) | 2005-04-08 | 2011-05-18 | Amylin Pharmaceuticals, Inc. | Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent |
US7955305B2 (en) | 2005-05-06 | 2011-06-07 | Medtronic Minimed, Inc. | Needle inserter and method for infusion device |
US20060280795A1 (en) | 2005-06-08 | 2006-12-14 | Dexcel Pharma Technologies, Ltd. | Specific time-delayed burst profile delivery system |
US9447781B2 (en) | 2005-07-22 | 2016-09-20 | University Of Utah Research Foundation | Osmotically driven dispense pump and related components for use in high pressure applications |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
EP1922336B1 (en) | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
WO2007022518A2 (en) | 2005-08-19 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | New uses of glucoregulatory proteins |
SI1971362T1 (sl) | 2005-08-19 | 2015-03-31 | Amylin Pharmaceuticals, Llc | Eksendin za zdravljenje diabetesa in zmanjšanje telesne mase |
ES2586236T3 (es) | 2005-11-04 | 2016-10-13 | Glaxosmithkline Llc | Procedimientos para administrar agentes hipoglucémicos |
US8039432B2 (en) | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
EP2364735A3 (en) * | 2005-12-16 | 2012-04-11 | Nektar Therapeutics | Branched PEG conjugates of GLP-1 |
EP1973953A2 (en) | 2005-12-16 | 2008-10-01 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating obesity and related metabolic disorders |
JP5242415B2 (ja) * | 2006-01-18 | 2013-07-24 | フォアシーエイサー ファーマシューティカルズ インコーポレイテッド | 高い安定性を持つ薬理組成物 |
CA2646598C (en) | 2006-03-21 | 2014-08-19 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
CN101437945A (zh) | 2006-05-02 | 2009-05-20 | 阿克托杰尼斯有限公司 | 肥胖相关肽的微生物肠内递送 |
WO2007133778A2 (en) | 2006-05-12 | 2007-11-22 | Amylin Pharmaceuticals, Inc. | Methods to restore glycemic control |
CA2651855C (en) | 2006-05-30 | 2011-08-02 | Intarcia Therapeutics, Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
WO2008008363A1 (en) | 2006-07-11 | 2008-01-17 | Qps, Llc | Pharmaceutical compositions for sustained release delivery of peptides |
EP2066337A2 (en) | 2006-08-04 | 2009-06-10 | Amylin Pharmaceuticals, Inc. | Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen |
EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
MX2009003737A (es) | 2006-10-05 | 2009-06-16 | Panacea Biotec Ltd | Composicion inyectable en deposito y su procedimiento de preparacion. |
WO2008061355A1 (en) | 2006-11-24 | 2008-05-29 | Matregen Corp. | Glp-1 depot systems, and methods of manufacture and uses thereof |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
US20090022727A1 (en) | 2007-01-26 | 2009-01-22 | Alza Corp. | Injectable, nonaqueous suspension with high concentration of therapeutic agent |
US8262667B1 (en) | 2007-02-23 | 2012-09-11 | Holmed Corporation | Multi-diameter implant forceps |
US8236760B2 (en) | 2007-04-27 | 2012-08-07 | Cedars-Sinsai Medical Center | Use of GLP-1 receptor agonists for the treatment of short bowel syndrome |
EP2254559B1 (en) | 2008-02-08 | 2018-10-10 | Foresee Pharmaceuticals Co., Ltd. | Composition for sustained release delivery of proteins or peptides |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
AU2009214632B2 (en) | 2008-02-14 | 2015-02-19 | Reshape Lifesciences, Inc. | Treatment of excess weight by neural downregulation in combination with compositions |
US20110046071A1 (en) | 2008-03-05 | 2011-02-24 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer |
US20090234392A1 (en) | 2008-03-13 | 2009-09-17 | Depuy Spine, Inc. | Method for inserting a spinal fixation element using implants having guide tabs |
JP5792057B2 (ja) | 2008-04-01 | 2015-10-07 | モサメディックス・ビー.ブイ.MosaMedix B.V. | 創傷治癒における瘢痕形成を低減するための組成物および方法 |
JP5486588B2 (ja) | 2008-04-04 | 2014-05-07 | エンテロメディクス インコーポレイテッド | 糖調節のための方法およびシステム |
ES2552646T3 (es) | 2008-05-21 | 2015-12-01 | Amylin Pharmaceuticals, Inc. | Exendinas para disminuir el colesterol y los triglicéridos |
CN102176900B (zh) | 2008-09-17 | 2017-09-26 | 克艾思马有限公司 | 药物组合物和相关的给药方法 |
CA2739181C (en) | 2008-09-30 | 2017-03-14 | Endo Pharmaceuticals Solutions Inc. | Implantable device for the delivery of risperidone and methods of use thereof |
NZ592113A (en) | 2008-10-15 | 2012-04-27 | Intarcia Therapeutics Inc | Highly concentrated drug particles, formulations, suspensions and uses thereof |
US20100298840A1 (en) | 2009-05-22 | 2010-11-25 | Schwartz Lyman D | Phimosis Treatment Device and Method |
US9358064B2 (en) | 2009-08-07 | 2016-06-07 | Ulthera, Inc. | Handpiece and methods for performing subcutaneous surgery |
EP3323423B1 (en) | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
JO2976B1 (en) | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Axentomodulin polypeptide |
US8263554B2 (en) | 2010-06-09 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | Methods of using GLP-1 receptor agonists to treat pancreatitis |
USD669589S1 (en) | 2010-08-31 | 2012-10-23 | Koninklijke Philips Electronics N.V. | Blood system cartridge |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
JP6396211B2 (ja) | 2011-07-04 | 2018-09-26 | インペリアル・イノベイションズ・リミテッド | 新規化合物及び摂食行動に対するそれらの効果 |
US20130098928A1 (en) | 2011-09-16 | 2013-04-25 | Golden Aluminum, Inc. | Application of designs to portion of food container |
CN104302236A (zh) | 2012-04-19 | 2015-01-21 | 瑞福德有限公司 | 用于去除皮肤下植入物的工具 |
EP2856940B1 (en) | 2012-05-29 | 2020-05-06 | National University Corporation Kochi University | Artery imaging device, and artery visualization device and method |
US20140058425A1 (en) | 2012-08-27 | 2014-02-27 | Amir Porat | Manually operated surgical devices with operative portions formed of a see-through material |
US9332995B2 (en) | 2012-09-25 | 2016-05-10 | Russo Inventions, Llc | Bone-harvesting tool |
KR20150119839A (ko) | 2012-11-19 | 2015-10-26 | 브래번 파마슈티컬즈 비브이비에이 에스피알엘 | 삽입형 약물 전달 조성물들 및 이의 치료 방법들 |
AU2016270984B2 (en) | 2015-06-03 | 2021-02-25 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
-
2008
- 2008-04-22 ES ES08743213T patent/ES2402172T3/es active Active
- 2008-04-22 JP JP2010506245A patent/JP5351884B2/ja active Active
- 2008-04-22 EP EP08743213A patent/EP2157967B1/en active Active
- 2008-04-22 CA CA2683610A patent/CA2683610C/en active Active
- 2008-04-22 WO PCT/US2008/005235 patent/WO2008133908A2/en active Application Filing
- 2008-04-22 CN CN201610052787.5A patent/CN105688191A/zh active Pending
- 2008-04-22 US US12/148,896 patent/US8299025B2/en active Active
- 2008-04-22 AU AU2008244523A patent/AU2008244523B2/en active Active
- 2008-04-22 KR KR1020097021476A patent/KR101208381B1/ko active IP Right Grant
- 2008-04-22 CN CN200880012205A patent/CN101715340A/zh active Pending
- 2008-04-22 RU RU2009143016/15A patent/RU2440097C2/ru active
- 2008-04-22 CN CN201410262400.XA patent/CN104000779A/zh active Pending
- 2008-04-22 PT PT87432134T patent/PT2157967E/pt unknown
- 2008-04-22 MX MX2009011123A patent/MX2009011123A/es active IP Right Grant
- 2008-04-22 NZ NZ580447A patent/NZ580447A/en unknown
- 2008-04-22 DK DK08743213.4T patent/DK2157967T3/da active
- 2008-04-22 PL PL08743213T patent/PL2157967T3/pl unknown
-
2009
- 2009-09-24 IL IL201175A patent/IL201175A/en active IP Right Grant
-
2010
- 2010-07-08 HK HK15100822.7A patent/HK1200336A1/xx unknown
- 2010-11-15 US US12/927,432 patent/US8940316B2/en active Active
-
2013
- 2013-03-22 HR HRP20130259AT patent/HRP20130259T1/hr unknown
- 2013-04-08 CY CY20131100290T patent/CY1114178T1/el unknown
- 2013-08-23 JP JP2013173812A patent/JP6016733B2/ja active Active
-
2014
- 2014-11-20 IL IL235813A patent/IL235813A/en active IP Right Grant
-
2015
- 2015-01-26 US US14/605,348 patent/US20150258016A1/en not_active Abandoned
-
2016
- 2016-09-26 JP JP2016187105A patent/JP6802019B2/ja active Active
- 2016-10-12 US US15/291,523 patent/US9682127B2/en active Active
- 2016-12-15 HK HK16114320A patent/HK1225966A1/zh unknown
-
2017
- 2017-03-05 IL IL250929A patent/IL250929B/en active IP Right Grant
- 2017-06-02 US US15/612,581 patent/US10363287B2/en active Active
-
2018
- 2018-10-12 JP JP2018193825A patent/JP2019048815A/ja active Pending
-
2020
- 2020-01-06 JP JP2020000461A patent/JP2020094055A/ja active Pending
-
2021
- 2021-01-17 IL IL280217A patent/IL280217B/en unknown
- 2021-07-30 JP JP2021125462A patent/JP2021178848A/ja active Pending
-
2022
- 2022-02-23 IL IL290847A patent/IL290847A/en unknown
-
2023
- 2023-10-02 JP JP2023171430A patent/JP2023166021A/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007501812A (ja) * | 2003-08-08 | 2007-02-01 | ノボ ノルディスク アクティーゼルスカブ | ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用 |
WO2006017852A2 (en) * | 2004-08-12 | 2006-02-16 | Quest Pharmaceutical Services | Pharmaceutical compositions for controlled release delivery of biologically active compounds |
WO2006084139A2 (en) * | 2005-02-03 | 2006-08-10 | Intarcia Therapeutics, Inc. | An implantable interferon-containing device |
WO2006083761A2 (en) * | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
WO2006087354A2 (en) * | 2005-02-16 | 2006-08-24 | Novo Nordisk A/S | Insulinotropic agents conjugated with structurally well defined branched polymers |
WO2006111169A1 (en) * | 2005-04-21 | 2006-10-26 | Gastrotech Pharma A/S | Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug |
WO2006131730A1 (en) * | 2005-06-06 | 2006-12-14 | Camurus Ab | Glp-1 analogue formulations |
JP6016733B2 (ja) * | 2007-04-23 | 2016-10-26 | インターシア セラピューティクス,インコーポレイティド | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6802019B2 (ja) | インスリン分泌促進性ペプチドの懸濁製剤及び使用 | |
ES2650667T3 (es) | Rápido establecimiento y/o terminación de la administración sustancial de fármaco en estado estacionario | |
CA2602249C (en) | Peptide and protein formulations with improved stability | |
TW201808989A (zh) | 升糖素受體選擇性多肽和彼之使用方法 | |
JP2005537232A (ja) | アミリンアゴニストペプチドの製剤 | |
US11246913B2 (en) | Suspension formulation comprising an insulinotropic peptide | |
JP2020510028A (ja) | 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181112 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20190903 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200303 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200804 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201102 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210204 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210330 |